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Abstract
The structure of the unique metal-binding protein, metallothionein (MT), consists of two
metal-thiolate-clustered binding domains; the β-domain binds up to three divalent metals and
the α-domain binds four. The mechanisms through which the metals are bound and arranged
into domains, as well as the function of MT in metal ion homeostasis, remains largely
unknown. By utilizing electrospray ionization mass spectrometry (ESI MS) to identify each
species, and by comparing the data with simulations, MT 1a was found to bind Zn2+ noncooperatively. Through a competition experiment between MT and its individual domain
peptides, MT was proposed to bind Zn2+ using terminal cysteines initially (into five strong
binding sites) before formation of the clusters with binding of the sixth and seventh Zn2+
(into two weaker binding sites). The terminally bound Zn5-MT intermediate is thought to be
key to metal acquisition (from zinc-chaperones) and donation (to zinc-dependent apoenzymes) in maintaining intracellular zinc homeostasis.
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Introduction
1.2 Metals in Biology

Biological systems are composed of elements readily found in the environment. Aside
from the obvious elements that make up the majority of organic structures and
metabolites (i.e., carbon, hydrogen, oxygen, and nitrogen), additional elements are
essential in large amounts (e.g., sodium, potassium, calcium, magnesium, phosphorus,
sulfur, iodine, and chlorine) or in smaller amounts (e.g., manganese, iron, cobalt, nickel,
copper, zinc, molybdenum, boron, silicon, and selenium) by most, if not all, biological
systems (1). Other elements are potentially essential for a select few organisms (e.g.,
barium, tungsten, cadmium, tin, arsenic, and bromine) (1).
Throughout evolution, the variety and abundance of metals available to organisms has
changed.

In particular, the liberation of dioxygen through photosynthesis had an

enormous impact on the solubility of metals (1). Prior to the shift toward an oxygenic
atmosphere, the concentration of sulfide in the ancient oceans was high and, therefore,
the majority of metal ions were in metal sulfide complexes (2). Under these conditions,
copper, zinc, and cadmium were inadequately available to organisms, while cobalt, nickel
and iron were more available for use in enzymes (2). As levels of oxygen in the
atmosphere increased, copper and zinc became more soluble, but cobalt and iron formed
hydroxyl complexes and thus became less bioavailable (2). Metal availability in the
archaic oceans is an important consideration when contemplating the trace metal
composition of organisms because the biological chemistry inside cells is essentially
chemistry in water.
Changes in the bioavailability of metals can be inferred from the utilization of metals in
increasingly more complex organisms as they evolved. Bacteria and archaea evolved in
the ancient oceans under anoxic conditions where iron was soluble (i.e., ferrous iron,
Fe2+) and therefore these organisms exploited the redox potential of iron in many
enzymes. Bacteria and archaea have proportionally more iron-sulfur proteins, but fewer
heme proteins than eukaryotes (3). In the oxygenic environment present today, iron is
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poorly soluble (i.e., ferric iron, Fe3+) and, therefore, plants and bacteria use siderophores
and reductases to scavenge what little iron is available (4, 5).
As eukaryotic genomes became increasingly more complex, zinc and copper were used in
an increasing number of metalloproteins (2, 6, 7). Zinc is probably most commonly
known for its role in zinc finger proteins; zinc finger motifs are prevalent in transcription
factors, which control the expression of genes associated with differentiation of cell types
(2). Copper proteins are most commonly used in electron transport chains for aerobic
respiration and photosynthesis (7). In addition, concentrations of both zinc and copper
are maintained in the cytoplasm of cells through metal importers, exporters, and metal
storage proteins (2).

1.2.1

Essential Metals

Thirteen metals are known to be required in specific quantities for the proper functioning
of plants and animals (8).

Group one and two metals (i.e., sodium, potassium,

magnesium, and calcium) are required in large amounts and are thus referred to as bulk
metals. The d-block metals (i.e., vanadium, chromium, manganese, iron, cobalt, nickel,
copper, zinc, and molybdenum) are required in smaller quantities and are thus referred to
as trace metals (1). Much is known about the bulk metals and their roles in mammalian
systems possibly through the sheer quantities of these elements in animals, but much
remains unknown about some of the trace metals and their roles in metabolism.
Manganese is well known for its role in the oxygen-evolving complex of photosystem II,
but also has a number of other important roles including those in glycosylation and as an
antioxidant (1, 9, 10). Iron is well known for its role in hemoglobin and the transport of
oxygen in animals, although iron is a cofactor in both heme and non-heme proteins,
which catalyze a great number of reactions in plants and animals (such as nitric oxide and
carbon dioxide transport, as well as electron transport) (11, 12).
Copper and zinc increased in bioavailability after atmospheric dioxygen appeared in
substantial quantities. Because of its availability and because of its redox potential,
copper is found in all plants and animals as an essential electron donor and acceptor in a
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multitude of cuproproteins; copper is key to energy production in most eukaryotes (1).
Because free copper can be highly detrimental, a number of proteins and enzymes are
responsible for regulating intracellular copper concentrations (1). Zinc is essential to
almost all species. Arguably, the most important roles of zinc are in development,
growth, and healing, with particularly significant functions in DNA replication and
translation, and mammalian respiration (1, 13). Similar to copper, the abundance of zinc
is tightly regulated in living systems; however, this is more likely due to the wide usage
of zinc and the severe effects of zinc deficiency rather than any detrimental consequences
of free zinc.

1.2.2

Toxic Metals

A number of metals are known to be toxic to humans and other mammals (e.g., lead,
arsenic, mercury, cadmium, and uranium), although all the essential metals can become
toxic at high concentrations. Some metals are essential at one oxidation state and toxic at
another (e.g., chromium (III) is essential; chromium (VI) is toxic (14)) or some metals
may be detrimental, or more detrimental, in complexes (e.g., mercury is generally toxic,
but methyl mercury is one of the most toxic metallocomplexes (15)). Some toxic metals,
such as lead, mercury, and cadmium are thought to enter cells through essential metal
transporters or pumps (16). Some metal ions may also pass through the cell membrane
alone or in complex with proteins or small molecules (16). Once inside the cell, toxic
metals often outcompete essential metals for binding sites in enzymes (e.g., cadmium can
easily replace zinc (15, 17)), causing the toxic effects.
Lead can replace calcium, leading to the deposition of lead in bone, and learning
deficiencies when lead replaces calcium in protein kinase C (an important protein in
signal transduction pathways) (18). Lead can also replace zinc and iron in enzymes
leading to developmental delays, learning disabilities, and behavioural problems in
children (18, 19). Possibly the most adverse effect of lead exposure is nervous system
damage; lead can cross the blood-brain barrier and lead to encephalopathy (19).
Depending on the mode of exposure and whether exposure is acute or chronic, arsenic
can cause a number of health problems (e.g., skin lesions, pulmonary edema, and liver
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failure) and is a known carcinogen (20). Arsenic uptake occurs through phosphate,
glucose, and glycerol transport pathways in prokaryotes and eukaryotes (21). Arsenic
causes damage through multiple mechanisms, including oxidative stress, cell membrane
disruption, and destruction of hemoglobin (20). Surprisingly, some evidence suggests
that arsenic may be essential to some organisms (22).
Cadmium is toxic to plants, causing symptoms such as growth retardation, inhibition of
photosynthesis, and generation of free radicals to name a few (23). Some plants have
adapted to cadmium-contaminated environments by accumulating or sequestering
cadmium, synthesizing phytochelatins (i.e., metal ion chelators) and inducing heat shock
proteins (23). In herbivores, the effects of cadmium toxicity can been seen in the lungs,
heart, liver, and kidneys (15). The majority of the toxic effects of cadmium exposure
may be attributed to the substitution of cadmium in zinc enzymes, although cadmium also
interferes with redox sensitive systems (15, 17).

The latter is attributed to the

replacement of iron in iron-requiring redox enzymes (15, 17).

1.3 Homeostasis of Metals
The concentrations of metal ions, like many other compounds, are usually maintained
within a set range regardless of the concentration of metals in the environment. Proteins
that bind metals (metalloproteins) are required to maintain this equilibrium.

If

intracellular metal ion concentrations are not maintained at precise levels, a number of
diseases and detrimental effects may result.

For example, in mammals, copper

imbalances may lead to Wilson’s or Menkes disease (24), zinc deficiencies may lead to
growth retardation (25), and iron imbalances may lead to haemochromatosis or anemia
(26).

1.3.1

Role of Metalloproteins

More than 30% of all proteins utilize a metal ion to perform their function and almost
50% of all enzymes contain a metal cofactor (2, 8). Metal ion cofactors are often crucial
to protein structure and function. These cofactors may aid in the catalysis of reactions,
act as electron acceptors or donors, or serve an exclusively structural function. Other
proteins bind essential metals to transport, store, or otherwise regulate the concentration
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of metal ions available to a cell. Proteins bound to their respective metal ion are referred
to as ‘holo’; proteins without their cofactor are referred to as ‘apo’.
Iron and copper are redox-active metals (i.e., can switch between oxidized and reduced
forms) and are often involved in electron transfer (e.g., heme-binding cytochromes and
blue-copper proteins in respiration and photosynthesis) and in the storage and transport of
dioxygen (e.g., hemoglobin, myoglobin, and hemocyanin) (2, 27). Zinc is a superacid
center in metalloproteins that promotes hydrolysis or cleavage of chemical bonds.
Enzymes such as carboxypeptidases, carbonic anhydrase, and alcohol dehydrogenase
contain catalytic zinc sites; however, many proteins contain zinc sites that have an
exclusively structural role (e.g., superoxide dismutase and zinc fingers) (2). Other trace
metals have also been identified as cofactors in metalloproteins.

For example,

manganese is a cofactor in mitochondrial superoxide dismutase, inorganic phosphatase,
and photosystem II; nickel functions in enzymes such as urease and numerous
hydrogenases; and molybdenum and vanadium are found in nitrogenases, along with iron
(2).
Proteins that store and transport metals, are required to maintain metal ion homeostasis.
For example, in mammals, copper is believed to be absorbed from the stomach and small
intestine by metallothionein and albumin, transported through the blood via albumin, and
delivered to the organs that require copper (i.e., mainly the liver, brain, heart, and
kidneys) (24). At the cellular level, copper is delivered to membrane-bound transporters
(e.g., eukaryotic CTR or bacterial CopA) by copper chaperones (e.g., bacterial CopZ)
(28-30). Once inside the cell, copper is transferred via a number of chaperones before
being inserted into the Cu-dependent apo-enzyme. In yeast, Cox17 delivers copper to the
intermembrane space of the mitochondria to be incorporated into cytochrome c oxidase
(i.e., the last enzyme in the electron transport chain of aerobic respiration), and CCS
delivers copper to cytoplasmic superoxide dismutase (detoxifies superoxide radicals
utilizing the redox cycling of bound copper) (30).
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1.3.2

Structure of Metal Binding Sites

Amino acids that regularly act as metal ligands in proteins are the thiolates of cysteines,
the imidazoles of histidines, the carboxylates of glutamic and aspartic acids, and the
phenolates of tyrosines (8). Metal cofactors act as Lewis acids and protein ligands act as
Lewis bases (31), generally following the hard-soft theory of acids and bases (i.e., the
Pearson acid base concept (32, 33)). This concept is often used in transition metal
chemistry to characterize the stability of compounds, reaction mechanisms, and
pathways. The term 'hard' describes small, highly charged, weakly polarizable species,
whereas the term 'soft' applies to large, low-charge species that are strongly polarizable
(34). Essentially, the theory predicts that soft acids (e.g., metals such as Cu+ and Cd2+)
will react faster and form stronger bonds with soft bases (e.g., S- from cysteine), whereas
hard acids (e.g., Mg2+ and Ca2+) will react faster and form stronger bonds with hard bases
(e.g., OH- from tyrosine, or NH+ from histidine).
Proteins may perform different types of biological functions, depending on the metal they
contain and its coordination. The coordination number and geometry of the metal site is
determined by the oxidation state of the metal, although distortions from the expected
structures often occur in metalloproteins.

For example, Cu2+ favours tetragonal

coordination, whereas Cu+ prefers tetrahedral or trigonal planar geometries (35). Many
copper chaperones in yeast (like those discussed above) have a GMXCXXC copperbinding motif, in which the two cysteines bind Cu+ in a low-coordination-number
environment (36). This coordination allows for tight binding while still allowing copper
transfer between binding domains of individual copper-binding proteins (36). In blue
copper proteins, which catalyze redox reactions in many organisms, another unexpected
copper binding site geometry is evident. From a crystal structure of plastocyanin, the
copper is believed to be bound by a cysteinyl thiolate, two histidine residues, and
possibly a rather distant methionine sulfur (35). The binding sites of blue copper proteins
appear to be constrained such that the geometry does not change upon oxidation or
reduction of the copper ion (35). This is thought to aid in the redox activity of the metal
center by ensuring that neither conformation is more stable than the other.
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Zinc is considered a ‘borderline’ metal and therefore binds a range of soft, hard, and
borderline ligands, including the carboxylate groups of aspartate and glutamate,
phosphates, histidine imidazoles, cysteine thiolates, and even water or hydroxide ions
(37). Depending on the ligands, the zinc site may simply aid in the structure of the
protein, or the zinc site may facilitate reaction catalysis. In structural sites, where Zn2+ is
usually bound to a mixture of nitrogen from histidine and sulfur from cysteine, the
coordination number is usually four and Zn2+ is usually bound in a tetrahedral geometry
(38). In catalytic sites, where Zn2+ is bound to water in addition to nitrogen from
histidine, sulfur from cysteine and, often, oxygen from either aspartic or glutamic acid,
the coordination number may increase from four to five, or from five to six (38).

1.3.3

Binding Mechanisms

Exactly how metals are bound or inserted into proteins is a topic currently receiving quite
a bit of attention. Some metallochaperones transfer metal ions directly from influx
transporters on the cell membrane to metalloproteins that require them to function (e.g.,
the copper chaperones mentioned above) although others do not appear to require
chaperones. For many proteins, the mechanism of metal binding remains unknown, often
because of the many problems of studying proteins in vitro in an attempt to elucidate in
vivo reactions.
Metalloproteins that bind more than one metal or substrate molecule(s) may bind through
different mechanisms that can be measured in kinetics studies. Binding constants (KFs)
are used to describe the binding site affinity, or how strongly the substrate is held within
a binding site. If binding of the first substrate increases the affinity (KF) for additional
molecules at another site, substrate binding exhibits positive cooperativity (39).
Conversely, if binding of the first substrate lowers the KF of subsequent molecules,
substrate binding exhibits negative cooperativity (39). If substrate binding at each site is
independent of the others, the binding is non-cooperative.
Most enzymes do not show any cooperativity in substrate binding, but there are a number
of examples of both positive and negative cooperativity in substrate binding by various
proteins (40). Oxygen binding to hemoglobin is one example of positively cooperative
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substrate binding (41). Hemoglobin is a tetrameric protein that contains four hemes (i.e.,
one in each subunit), each of which binds a dioxygen molecule. Binding of the first
dioxygen increases binding of additional oxygen molecules, such that the fourth and last
dioxygen binds with the highest affinity (KF).
ATP-citrate lyase is an example of an enzyme that exhibits negative cooperativity in
binding its substrate, citrate. ATP-citrate lyase is a tetrameric enzyme with four identical
subunits; it is a key enzyme in the reductive tricarboxylic acid cycle, which is the carbon
dioxide fixation pathway in bacteria (42). ATP-citrate lyase uses ATP to catalyze the
conversion of citrate and CoA into acetyl-CoA and oxaloacetate (42). Citrate binding to
ATP-citrate lyase demonstrates negative cooperativity; binding of the first and second
citrate molecules significantly decreases the affinity of the enzyme for subsequent citrate
molecules (42).

1.4 Zinc Homeostasis
Zinc, the most abundant trace metal ion in aerobic cells, is an essential cofactor of
numerous enzymes, which have roles in a wide range of biochemical pathways. For
example, Zn2+ is a structural component in growth factors, cytokines, receptors, and
transcription factors belonging to a number of cellular signaling pathways (43, 44). Zinc
thus has a role in a large number of cellular processes from DNA and protein synthesis to
mitosis and cell division (45). Because Zn2+ is vital to so many processes, levels are
tightly regulated both at the cellular level and at the organismal level. Zinc binding in
enzymes is very strong, with binding constants on the order of 1011 M-1 (1). Cellular Zn2+
levels are tightly controlled by transporters (46), channels (47), Zn2+ sensing storage
proteins (i.e., MTs; (48)), and transcription factors (e.g., MTF-1; (25, 49)), such that the
concentration of free Zn2+ is about 10-15 M in the cytoplasm (i.e., approximately one
unbound Zn2+ per cell) (50). When levels of Zn2+ are unregulated, a number of health
problems, such as growth retardation, immunodeficiency, and neuronal and sensory
dysfunctions result (25).

Because zinc is directly involved in tissue synthesis,

manifestations of zinc deficiency in humans can be as severe as dwarfism (51).
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One major role of zinc in eukaryotes is in gene regulation through proteins containing a
zinc finger motif. In this way, the structural role of zinc extends to the organization of
chromosomes (52). Most zinc fingers bind to DNA promoters, but the zinc cofactor
appears to have a structural or regulatory role.

Zinc finger proteins regulate gene

expression, and as an extension mRNA and proteins, in a variety of pathways involved in
cell differentiation, the cell cycle, and even apoptosis and cancer (53). From the diversity
of proteins containing zinc finger motifs, and thus containing structural zinc-binding
sites, it is easy to see how zinc deficiencies can cause such profound effects.
The total zinc content of a cell is believed to be approximately 0.1-0.5 mM across a
number of study species including Escherichia coli, yeast, and mammalian cells,
although essentially all the zinc is bound to proteins (54).

The mechanism(s) that

controls the cellular zinc concentration has been the focus of much research since the
characterization of the first zinc transporter (55). Zinc transporters, responsible for zinc
influx and efflux, are thought to be key to maintaining intracellular zinc concentrations.
However, influx and efflux are not only important for maintaining the concentration of
zinc within a cell, but also for transporting zinc through epithelial cells in the intestine
into the bloodstream. Studies have also described zinc-sensing transcription factors that
control the influx and efflux of zinc into the cell (2). Hantke (56) provides an excellent
summary of the many zinc-binding proteins – including proteins involved in influx and
efflux – in the periplasm of Escherichia coli.

1.4.1

Zinc Influx

Because zinc is required in so many intracellular pathways and proteins, cells must have
mechanisms dedicated to bringing zinc across the cell membrane. Zinc influx proteins
are membrane-bound transporters that facilitate the movement of extracellular Zn2+ into
the cytoplasm. A number of different study species from bacteria to yeast to mammalian
cells have been examined in an attempt to elucidate the mechanisms of zinc influx into
cells. Each system has its own nomenclature, although the proteins are highly similar. A
number of zinc uptake systems, including the bacterial Znu proteins, the eukaryotic ZIP
proteins, and the yeast ZRT proteins, are thought to be essential in maintaining zinc
homeostasis.

10

A high-affinity zinc-uptake system has been found in many bacterial species. Three
proteins encoded by the znuA, B and C genes have been identified; these include a
periplasmic binding protein (ZnuA), a membrane permease (ZnuB), and an ATPase
(ZnuC) (56, 57). Expression of this system is believed to be regulated by zinc as well as
a bacterial repressor from the FUR family known as ZUR (57).
ZIPs (also known as ZRT, IRT-like proteins) have been found in many eukaryotes
including animals, plants, protists, and fungi. ZIPs were named for their similarity to
both the ZRT (the zinc regulated transporter) and IRT (the iron regulated transporter)
proteins described prior to the discovery of ZIPs. ZRT1 and ZRT2 are ATP-dependent
high- (KF of approximately 108 M-1) and low-affinity (KF of approximately 107 M-1) zinc
transporters in Saccharomyces cerevisiae, respectively (58, 59). Similarly, IRT1 is an
iron transporter in Arabidopsis thaliana (60).
Mammalian ZIPs are officially known as the SLC39 family of metal ion transporters and,
unlike yeast ZRT proteins, they do not appear to require ATP. The ZIP protein family
transports zinc (and/or other metal ions) from the extracellular space or from the lumen of
organelles into the cytoplasm (54). This protein family is large with an estimated 14 ZIPs
with differing localizations within cells and within organs.
The ZIP1 (SLC39A1) transporter is ubiquitously expressed in mice and human tissues
and is thought to be important in zinc uptake in a variety of cell types (61, 62). ZIP2
(SLC39A2) and ZIP3 (SLC39A3) are also believed to have roles in zinc uptake by
mammalian cells (63-65). ZIP3 appears to be particularly important in zinc uptake by
mammary epithelial cells to provide the milk with zinc (66). ZIP4 (SLC39A4) appears to
be an important transporter for zinc absorption from the intestine; mouse ZIP4 has been
localized to the apical membrane of the absorptive intestinal cells (54, 67).

ZIP5

(SLC39A5) also appears to be important in zinc absorption, although ZIP5 is expressed
on the basolateral membrane of intestinal enterocytes (Figure 1.1) (68). Thus, ZIP4
likely functions to transport zinc from the intestinal lumen into the enterocyte while ZIP5
transports zinc from the bloodstream into the enterocyte (54).

11

Figure 1.1. Schematic representation of the distribution of various Zn2+ influx and
efflux proteins throughout an enterocyte. This diagram was adapted from the work of
Wang and Zhou (67). Structures of these proteins were obtained from the Protein Data
Bank (‘MT’, 4MT2; ‘ZIP4’, 2CBN; other ZIPs, 2AJO; ‘ZnT1’, 3NWI; other ZnTs,
2ENK) and illustrated in MacPyMol Molecular Graphics System (Version 1.5.0.4
©Schrödinger, LLC. 2010) (69-74). Where no structure was available, other protein
structures from the same protein family were used.
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1.4.2

Zinc Efflux

A number of studies have examined the mechanism of zinc efflux in an attempt to
determine how cells remove excess zinc. A family of zinc efflux transporters, known as
CDF, ZnT, or SLC30, depending on the organism, has been the focus of much
investigation over the last 15 to 20 years. The most well defined members of this protein
family include the bacterial CDF (cation diffusion facilitator) and mammalian ZnT
(SLC30) (75, 76). The name, ‘cation diffusion facilitator’ is deceiving; CDF proteins do
not actually operate as diffusion facilitators but, instead, use existing gradients to drive
the transport of zinc, similar to secondary active transporters (54). This family of metal
ion transporters invariably transports zinc (and/or other metal ions) from the cytoplasm of
the cell either into the lumen of intracellular organelles or into the extracellular space
(Figure 1.1) (54).
Similar to a number of ZIPs, ZnT1 (SLC30A1) is thought to have a role in the absorption
of dietary zinc and has been localized to the basolateral membrane of mammalian
enterocytes (77, 78). ZnT1 is thus thought to efflux absorbed dietary zinc from the
enterocyte into the bloodstream (77). Other ZnT proteins have been localized to various
organelles or even organs, although their roles are less understood. For example, ZnT3
(SLC30A3) is confined to the brain and testis of rats, and ZnT2 (SLC30A2) and ZnT4
(SLC30A4) are expressed in rodent intestine, although they were expressed only in
intracellular vesicle membranes (79, 80). From this observation, it seems plausible that
ZnT2 is involved in the storage or excretion of zinc from enterocytes with high zinc
influx (67). ZnT4 has also been localized to the trans-Golgi network and may promote
zinc secretion into the blood stream through exocytosis (81).

ZnT6 (SLC30A6) is

thought to form a complex with ZnT5 (SLC30A5) and activate zinc-dependent enzymes
in the secretory pathway, although ZnT6 may also function to excrete zinc from
enterocytes into the intestinal lumen through exocytosis (67, 82). ZnT7 (SLC30A7) is
localized primarily to the Golgi apparatus and is thought to have a role in the
incorporation of zinc into membrane-bound or secreted enzymes (82, 83).
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1.4.3

Zinc Sensing

The concept of proteins that could ‘sense’ zinc levels significantly changed the
understanding of zinc homeostasis. These zinc-sensing proteins are transcription factors
that can alter the expression of zinc transporters and storage proteins based on the
intracellular zinc concentration. The transcription factor, MTF1 was one of the first such
zinc sensors to be characterized. MTF1, or metal response element-binding transcription
factor 1, is a zinc finger protein that was found to induce transcription of metallothionein
(zinc storage) when cells were treated with zinc (84). Little is known about zinc sensing
proteins; the mechanism by which they ‘sense’ zinc levels and influence the transcription
of zinc influx and efflux proteins has yet to be identified in most cases. Thus far, the
known (and fairly well described) zinc sensing proteins include ZUR (a member of a
family of uptake regulators), ZiaR (a repressor of a heavy metal transporter, ZiaA), ZnTR
(a repressor of a zinc efflux transporter, ZnTA) and ZAP1 (a zinc influx regulator).
When bound to zinc, ZUR binds DNA and represses transcription of zinc uptake systems,
including znuABC, ycdH, and yciC (1).

ZUR is a member of a family of uptake

regulators, along with FUR (an iron sensing transcriptional regulator), found in bacteria.
Interestingly, FUR has a zinc-binding site and ZUR has an iron-binding site. In both
cases, the zinc site is tetrahedral, utilizing two thiolate ligands and most likely a nitrogen
from histidine, and the iron site is octahedral, known to utilize histidines and carboxylates
(1). ZUR is thought to respond to zinc with a binding affinity of up to 1015 M-1 (50).
ZiaR is a zinc-responsive repressor of ziaA, which encodes an efflux transporter, ZiaA.
ZiaR is a member of the ArsR family of metalloregulatory proteins which includes SmtB
and ArsR (85). ZiaR contains one-high affinity zinc site, with a KF > 1011 M-1, which is
thought to utilize at least one histidine and a cysteine (85).
ZnTR is a member of a family of MerR repressors. ZnTR, similar to ZUR, is thought to
bind zinc with an affinity of up to 1015 M-1 and activate transcription of zinc efflux
proteins, specifically the zinc efflux pump, ZnTA (50, 86). ZnTR functions as a dimer,
binding two zinc ions per dimer, whereas ZnTA is a P-type ATPase transporter that
consumes ATP to catalyze zinc export (86).
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ZAP1 is a zinc-responsive transcriptional regulator that senses intracellular zinc levels
and changes the expression of Zn2+ binding proteins (87, 88). The mechanism of this
regulation is essentially unknown, although ZAP1 (a zinc finger protein) has been shown
to bind to the ZRE (the zinc responsive element) sequence upstream of a number of zincregulated genes such as the ZIP protein family and the ZRT proteins (87, 89). There is
some evidence to suggest that ZAP1 may act as both a transcriptional activator and a
repressor in the regulation of ZRT1 and ZRT2 (90).
Although there has been a significant amount of recent research delving into the
mechanisms of zinc homeostasis, even the simplest prokaryotic systems have not been
satisfactorily described because they are too complex. Most likely, many more proteins
are involved in the transport of zinc throughout the cell than those that are currently
known. Proteins with roles in the trafficking of zinc through cells, either from influx
transporters to zinc requiring apo-enzymes or from influx to efflux transporters in
intestinal cells, remain largely undefined. However, metallothionein is believed to have a
role in the transport and storage of zinc, though the exact nature of this function is largely
unknown. Metallothionein is the focus of this thesis, and is described in detail below.

1.5 Metallothionein
Initially isolated by Margoshes and Vallee in 1957 from horse kidney cortex (91),
metallothioneins are a group of relatively small metalloproteins (approximately 4 to 8
kDa (92)) with a high cysteine content (~30% of the total amino acids (93)), but no
disulfide bonds or aromatic amino acids (94-96). Metallothioneins were named for their
unusually high metal (metallo) and sulfur (thiol) content.

Members of the

metallothionein (MT) family have been found to have cys-x-cys homology in organisms
from bacteria (97) to fungi (98), to plants and mammals (99).

Another unique

characteristic of metallothioneins is the structure and metallation chemistry, which is
dictated by the metal-thiolate bonds (100-102).
The best-characterized MTs are the mammalian MTs, which are composed of 60-80
amino acid residues (twenty of which are cysteines) and are able to coordinate multiple
metal ions. The mammalian MT family is further subdivided into four subfamilies,

15

which are proposed to have specific functions in different tissues. Found in the liver and
kidneys, MT 1 and MT 2 may be induced by metal ions, glucocorticoids and cytokines,
as well as oxidative stress (103). MT 3 is primarily found in the brain, although it has
also been detected in cells of the kidney, testes, and the tongue (104, 105). MT 4 is
specifically expressed in stratified squamous epithelia, which are protective layers on the
surface of tissues such as the skin, tail, and tongue in rodents (106, 107). The expression
of MT 3 and MT 4 is more strictly controlled than that of MT 1 or MT 2. These
differences in expression may be due to the potential detrimental effects if metal ion
homeostasis is disrupted in the particular tissues where MT 3 and MT 4 are most often
localized (108-110).
Many transition metals, specifically d10 metals, such as Zn2+ and Cu+, are known to bind
these unique sulfur-rich proteins in vivo. MT is believed to be important in copper and
zinc homeostasis, but also aids in toxic metal detoxification and the reduction of
oxidative stress. MT binds as strongly to toxic metals, such as Cd2+, Hg2+, and As3+, as it
does to essential metals, like Zn2+ and Cu+, because of its twenty cysteinyl thiols –
following the Irving-Williams series (Mn2+ < Fe2+ < Co2+ < Ni2+ < Cu2+ > Zn2+) (111113).
X-ray diffraction and NMR studies of rat liver MT 2 and rabbit liver MT 1, saturated
with Zn2+ and Cd2+, showed that the bound metal ions are arranged into two distinct
metal-thiolate clustered binding domains using terminal and bridging cysteinyl thiolate
ligands (69, 114, 115). The N-terminal β-domain may bind up to three Zn2+, three Cd2+
or six Cu+ using nine cysteines, while the C-terminal α-domain binds up to four Zn2+,
four Cd2+ or six Cu+ using eleven cysteines (Figure 1.2) (114, 116-118).

1.5.1

The Structure of Apo-Metallothionein

The majority of research has investigated the metallation properties of MT, specifically
examining the structure of the saturated holo-protein. In vitro metallation studies begin
by adding metals to either the apo-protein (119-121) or to the holo-protein (if bound to
metals lower in the Irving-Williams series of affinities) (122, 123). For example, many
metals can displace Zn2+ either isomorphously (e.g., Cd2+; (124)) or by inducing a
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Figure 1.2. The sequence, structure, and location of Cd2+ binding in Cd7-MT 1a. A
space filling structure (A) and ball and stick models of the cadmium-cysteinyl-thiolate
clusters (B) of Cd7-βα-rhMT 1a are shown with the β-domain on the left and the αdomain on the right. (C) The sequence and metal connectivity diagram for MT 1a.
Numbering of the Cd-thiolate centers is based on NMR studies by Messerle et al. (1990)
(116). Adapted with permission from Sutherland, D. E. K., Summers, K. L., and
Stillman, M. J. (2012) Noncooperative metalation of metallothionein 1a and its isolated
domains, Biochemistry 51: 6690-6700. © 2012 American Chemical Society.
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structural change (e.g., Cu+; (125)). Metallation is expected to be completely different
depending on the starting metallation state of the protein; metallation from the apoprotein is not the same as from the saturated holo-protein. There are benefits to using the
holo-protein as the basis for these studies. Primarily, the metals protect the twenty
cysteinyl thiols from oxidation (especially at near neutral, physiological pH where the
sulfurs are particularly vulnerable). Additionally, toxic metal binding (e.g., Cd2+) by
liver metallothioneins in vivo would likely occur through the displacement of Zn2+; this
released Zn2+ then induces the expression of de novo metallothionein.
Initial posttranslational metallation of metallothioneins, however, would begin with the
nascent apo-protein. Although studying the apo structure may aid in understanding this
key initial metallation step, determining the structure of the apo-peptide is complicated
because it is highly fluxional and does not contain chromophorically useful residues. To
circumvent these problems, molecular modelling was used to explore the apo-protein
structure and suggested that the metal-free protein was loosely folded into a globular
sphere with the thiols exposed on the surface of the protein (126-129). Any tertiary
structure of MT is based on the metal coordination geometries; without metals, the apoprotein may still be described as a random-coil.
Recent electrospray ionization mass spectra provided novel experimental structural data
for apo-MT (130). Similar to that predicted from molecular modelling (126-129), the
charge state distribution of the apo-protein at physiological pH was more comparable
with the Zn7-protein than to the acid-denatured apo-protein at pH 3 (Figure 1.3). The
main difference was that Zn7MT appeared to have a slightly larger structure, which is
attributable to a slight expansion of the globular structure to accommodate seven metal
ions.

1.5.2

Metal-Induced Folding

Protein structure is intimately linked to protein function. For many metalloproteins,
insertion of a metal ion cofactor is considered a post-translational modification and the
metal ion is inserted after the protein folds to accommodate it (131, 132). For other
metalloproteins, the metal is required for proper protein folding (131). To date, little is
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Figure 1.3. Charge state mass spectra and molecular models of apo- and holo-MT.
Charge state spectra and molecular models of denatured (pH 3) apo-βα-rhMT 1a (A),
globular (pH 7) apo-βα-rhMT 1a (B), two-domain holo-βα-rhMT 1a (C), and βα-rhMT 1a
bound to twenty benzoquinone cysteinyl modifiers (D). Adapted from Biochemical and
Biophysical Research Communications, 425, Summers, K. L., Mahrok, A. K., Dryden,
M. D. M., and Stillman, M. J., Structural properties of metal-free apometallothioneins,
485-492. © 2012 with permission from Elsevier.
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known about metalloprotein assembly and metal ion insertion, although there is much
research being conducted on the subject (8).
Azurin, an electron transferring blue-copper protein, does not require a metal ion for
folding, although protein folding is much faster when copper is present (8, 133). Because
there are essentially no free copper ions in the cytoplasm (due to the oxidative damage to
proteins, lipids, and nucleic acids that would result), copper is thought to be inserted into
the folded protein by a copper chaperone in vivo (8). Conversely, many zinc finger
proteins require Zn2+ binding to fold; metal coordination is thought to induce secondary
and tertiary structure formation (8).
Metallothionein is similar to the zinc finger proteins in that metal binding induces protein
folding. Although MT is described as a protein that undergoes folding, it does not have
defined secondary structures such as the α-helix and β-sheet present in the zinc finger
motif. In MT, the covalent metal-sulfur bonds define the structural properties. Unlike
proteins requiring a single metal ion cofactor, there is ambiguity in the position of metals
in partially metallated MT intermediates – in terms of metal coordination into specific
binding sites.

The metal-binding-induced structure of MT is believed to require

translation of the entire polypeptide chain before metallation and folding can occur (126).

1.5.3

Structure of Holo-Metallothionein

In the more than 50 years since the discovery of equine kidney MT, only two crystal
structures have successfully been obtained for the mammalian branch of this
metalloprotein family. The first structure, published in 1986 by Furey et al. (134), was of
rat liver MT 2 bound to five Cd2+ and two Zn2+; this structure was later refined by
Robbins, et al. in 1991 (114). In 2005, a structure of the yeast Cu8-MT was reported by
Calderone, et al. (135). These crystal structures provided important information on the
coordination of Cd2+ and Zn2+ (tetrahedral), and Cu+ (trigonal or digonal or a combination
thereof) to the cysteinyl sulfur ligands. Unlike the solution structures proposed by 113CdNMR (115, 136), 1H-NMR (102, 117, 136), XAFS (137, 138), and molecular modelling
(139), the crystal structures provided information about the domain linkage in addition to
information about the metal-binding sites and the individual domains. The structure of
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MT was described as a dumb-bell-like shape with two clustered metal binding domains
separated by a linker region (69, 114). The holo-structure is rigid, defined by metal ion
coordination, which can include digonal, trigonal, or tetrahedral geometries, or possibly
some combination (94). The stable saturated clusters resulting from complete saturation
with metal ions, are often characterized by the stoichiometric ratio of metal ions to
protein (usually from seven to eighteen metal ions per mammalian MT protein), which
depends on the metal and its preferred coordination (140).
Coordination of Zn2+ or Cd2+ was found to require both terminal (one cysteinyl sulfur
bound to one M2+) and bridging (one cysteinyl sulfur bound to two M2+) cysteines in each
domain (Figure 1.2).

In the N-terminal β-domain, six terminal and three bridging

cysteines bind three M2+; and in the C-terminal α-domain, six terminal and five bridging
cysteines bind four M2+. The two metal-thiolate clusters are believed to be arranged in a
way that allows the binding of multiple different metal ions in each domain. The twodomain structure is thus thought to aid in the maintenance of both Zn2+ and Cu+
homeostasis simultaneously (118, 141). In contrast to the X-ray structure (of rat liver
Cd5Zn2-MT; (69)), which depicts the characteristic dumb-bell shape, molecular models of
holo-MT suggest the domains may actually coalesce in solution (126).

1.5.4

Putative Functions

The putative functions of MT include toxic metal sequestration (e.g., Cd2+, Hg2+, As3+),
protection from oxidative stress, and essential metal trafficking and storage (e.g., Cu+ and
Zn2+). MT may bind to numerous ‘soft’ transition metals (and even some metalloids)
(e.g., Zn2+ (93); Cd2+ (93, 142); Hg2+ (143); Cu+ (144, 145); Ag+ (144); Au+ (144); Pt2+
(144); As3+ (111); Bi3+ (146); and Tc5+ (147)) because of its many thiols, but many of
these binding events have been demonstrated in vitro only and the biological relevance is
largely unknown. However, in studies examining the role of MT in metal detoxification,
particularly utilizing MT knockout organisms, the resistance to toxic metals diminishes
without MT. MT 1 and MT 2 knockout mice developed normally until exposed to
cadmium, at which point the mice died of hepatic damage, providing concrete evidence
that MT is important in reducing the toxic effects of cadmium exposure (148).
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Metallothionein may not only sequester toxic metals, but may also prevent the toxic
effects of essential metals. For example, MT may aid in the prevention of copper toxicity
simply by reducing or sequestering it (149). In particular, MT was reported to be
beneficial in alleviating the symptoms of both Menkes and Wilson’s disease. In Menkes
disease, copper accumulates in the kidneys and the intestinal wall, depriving the brain,
serum and liver of adequate copper (150). Using a mouse model of Menkes disease, in
which the MT 1 and MT 2 genes were inactivated, the mice were found to be more
susceptible to copper toxicity without inducible MT (150, 151). In Wilson’s disease,
copper accumulates in the liver, brain, and cornea, leading to cellular damage and the
eventual release of free copper into the blood (152). In studies on hepatocytes from
patients with Wilson’s disease, accumulation of Cu-MT instead of free copper ions was
found to lessen the cellular damage slightly (153).
MT is thought to have an important function as a protective agent against oxidative
stress. In fact, a redox cycle involving MT has been proposed in explanation of how MT
might fulfill this role within a cell (154). Reactive oxygen species oxidize MT, causing
the formation of disulfide bonds and the release of Zn2+. The released Zn2+ then upregulates Zn2+ binding proteins through MTF-1 binding. Subsequent reduction of the
cysteinyl sulfurs by glutathione, or synthesis of de novo MT, then re-establishes the
initial zinc balance.
MT has also been implicated in the trafficking and storage of essential metals like Cu+
and Zn2+. Zn7-MT has been shown to act as both a Zn2+ donor for apo-enzymes, such as
m-aconitase (155), carbonic anhydrase (156, 157) and Gal4 (158) and a Zn2+ acceptor in
the transfer of Zn2+ from Sp1 (a zinc finger protein) to MT (159). The presence of
partially metallated species has been noted during the donation of Zn2+ from Zn7MT to
metal ion chelators or to apo-enzymes (160-162), which could suggest that partially
metallated MT also functions in regulating intracellular Zn2+ concentrations.
Interestingly, a recent study has demonstrated that Zn7-MT 3 can exchange its bound
Zn2+ with the Cu2+ bound to the amyloid-β-peptide, resulting in the formation of Cu4Zn4MT 3 without the threat of cysteinyl thiol oxidation (109).
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Even after 50 years of research on the structure and function of MT, a few gaps remain in
our understanding. An explanation of how Zn7MT – with stronger binding affinities than
recipient apo-enzymes – donates Zn2+ is missing in the literature. As discussed above,
apo-MT is very flexible, without significant secondary structure (130); holo-MT is rigid,
dominated by the coordination geometry of the bound metal ions (94). Working with the
current understanding of how metallothionein binds and stores metals, donation of Zn2+
from the two-domain Zn7MT would cause the clustered binding sites to unfold and would
most likely lead to the exposure and subsequent oxidation of the cysteinyl thiols (154,
155, 157, 158).

1.6 Electrospray Ionization Mass Spectrometry
ESI is often referred to as a 'soft ionization' technique because there is very little
fragmentation during the ionization process, which can be advantageous for biological
samples that are defined by non-covalent interactions (e.g., metal binding to amino acids)
(163, 164). Particularly in the study of metallothioneins, ESI MS has permitted a much
better understanding of the metallation states of the protein. Because MT has no true
defined secondary structure, using spectroscopic techniques to study MT – especially the
apo-protein – is quite challenging (100-102). Additionally, the main metal ion stored by
mammalian MT, Zn2+, is spectroscopically silent (165). Consequently, a zinc substitute
is required to utilize many of the techniques typically used to study metalloproteins (e.g.,
UV absorption, CD and NMR spectroscopies). Cadmium has been used extensively for
this purpose because, structurally, cadmium coordination to thiols is essentially the same
as zinc and because, not surprisingly, Cd-MT and Zn-MT appear almost identical in
NMR structural studies (116, 117). The main benefit to studying cadmium, as compared
to zinc, is that the ligand-to-metal charge transfer associated with cadmium-thiolate
bonds is red shifted (to approx. 250 nm) compared to zinc-thiolate bonds (at approx. 230
nm) and therefore Cd-MT, unlike Zn-MT, can be monitored using both UV absorption
and CD spectroscopies (142). Cadmium also has a greater affinity for thiolate groups,
which provides increased protection for cadmium-saturated MT against oxidation (93,
166, 167).
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Although cadmium has been very effective in the elucidation of some aspects of zinc
binding in metallothionein, ESI MS has made the direct analysis of Zn-MT feasible (168170). Electrospray ionization mass spectrometry permits the determination of the mass
of the metal ions (and therefore allowing one to deduce which metal is bound) as well as
the number of metal ions bound to the protein (by analyzing the increase in the charge
state masses as compared to those of the apo-protein).

Conversely, spectroscopic

techniques are often capable of providing only an average of the total metals bound.
Prior to the more prevalent use of ESI MS to study metal-binding reactions, solutions of
MT were often assumed to contain only one metallated species (i.e., if four equivalents of
Cd2+ were added, this would result in the formation of 100% Cd4-MT); however, it is
now obvious that the addition of metal ions to solutions of MT results in a distribution of
metallated species (120). To date, ESI MS has provided a large amount of information
on the partially metallated intermediates in the MT metallation pathways of both essential
(e.g., Zn2+ (161) and Cu+ (171, 172)) and toxic metals (e.g., Ag+ (172), As3+ (111, 173175), Cd2+ (120, 176, 177), and Bi3+ (146)).

1.6.1

Metal Binding Studies

When observed by ESI MS, binding of metal ions to an apo-protein causes an increase in
the mass to charge ratio (m/z) that is proportional to the mass of the metal ion bound.
From the deconvoluted spectra, the stoichiometry of metals bound to the protein can
easily be determined because the difference in mass between the apo- and holo-proteins
should be some multiple of the metal ion of interest. Similarly, the relative distribution
of metallated species in a solution – in proteins like MT that bind multiple metal ions –
can now be monitored easily. Many of the metal binding studies conducted using ESI
MS are in fact on metallothioneins. ESI MS has been utilized in many metal-binding
studies of metallothioneins from a variety of organisms with a number of metals
including Cd2+ (92, 120, 176, 177), Zn2+ (92, 161), Cu+ (92, 121, 178), Ag+ (172), Bi3+
(146), and As3+ (111, 174, 175).
ESI MS techniques have also been employed in the study of other metal binding proteins.
For example, the calcium binding of parvalbumin and calmodulin has been investigated
by ESI MS (179). Cooperative binding in the two calcium-binding sites of parvalbumin
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was observed, and up to four Ca2+ were found to bind to calmodulin, with the last two
sites binding metal ions cooperatively (179). In another study, human insulin growth
factor 1 was found to bind four Cu+ ions cooperatively, possibly into a tetracopperhexathiolate cluster (i.e., Cu4S6) using ESI MS (180). In yet another ESI MS study, the
Escherichia coli protein SlyD, was found to bind up to seven Ni2+ non-cooperatively and
with sub-micromolar binding affinity (181).
ESI MS may also be used in structural studies of proteins, like metallothioneins, that
exhibit metal-induced folding. For example, ESI MS was used to show that binding of
the first Zn2+ to a vitamin D receptor results only in a slight conformational change, but
binding of a second Zn2+ results in a significant alteration in protein structure (182).

1.7 Scope of Thesis
The purpose of the research summarized in this thesis was to characterize the zinc
metallation of human metallothionein 1a using ESI MS. Initially, the metallation of each
individual domain peptide, and the full two-domain protein (Section 3.1), was examined
to determine if the protein exhibited any cooperativity in Zn2+ binding, as had been
proposed previously. Metallation of human metallothionein with Zn2+ was hypothesized
to occur non-cooperatively, similar to metallation with Cd2+, but in contrast to established
theories.
The first competition experiment (Subsection 3.2.1), in which the individual domains
compete for available Zn2+, was intended to determine if either domain bound the added
Zn2+ with a higher affinity. If this were the case, it could provide evidence for a domainspecific metallation mechanism where one domain was saturated prior to the filling of the
second domain. It was hypothesized that the α-domain would have a higher Zn2+ binding
affinity than the β-domain based on previous work and because the α-domain simply has
more binding sites than the β-domain (183, 184). However, some previous reports have
also suggested that the β-domain binds metals preferentially (145).
The second competition experiment (Subsection 3.2.2), in which the domain peptides
compete with the full protein for binding of the available zinc, was originally designed to
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investigate the role of the inter-domain, amino acid linker on Zn2+ binding. It was
hypothesized that the connected domains (i.e., the full two-domain protein) would bind
Zn2+ much more strongly than the separate domains, thus explaining the inherent
evolutionary advantage of a two-domain structure.
Because ESI MS is able to distinguish between each individual metallated species, it
proved to be a much more useful tool than others that detect an average of the total
species in solution. Through the use of this powerful tool, coupled with data simulations,
the Zn2+ binding mechanism for human MT 1a was elucidated. With this knowledge in
hand, and detailed molecular modelling and molecular dynamics calculations, a novel
metallation pathway for human MT 1a was proposed.

28

2

Methodology

The experiments described in this thesis utilized a recombinant version of human MT 1a
purified from an Escherichia coli expression system. Recombinant proteins are often
preferred over purification of proteins from live mammals. In addition to the more
obvious concerns around caring for live animals and later euthanizing them, the many
isoforms of mammalian metallothionein cannot be readily separated.

This may be

problematic because the different isoforms are known to have distinct roles and, most
importantly for studies using mass spectrometry, the isoforms have different masses.
The study of human MT in particular could not be studied in depth without the
expression of recombinant proteins in a host organism. Recombinant protein expression
simplifies protein isolation and purification, resulting in large quantities of one MT
isoform.

The use of a recombinant expression system also permits the design and

production of truncated versions of proteins. This attribute is particularly important to
the studies detailed herein because it permits the expression and purification of the two
domains of MT as individual peptides (β- and α-rhMT).

2.2 Protein Preparation
The expression and purification methods used to obtain human recombinant MT isoform
1a have been previously reported (185, 186). The details of the purification process are
provided below; in essence, recombinant human MT 1a was expressed in E. coli, purified
using both ion exchange and size exclusion chromatography, and the purity of the protein
assessed using UV absorption spectroscopy, before experimentation using ESI MS.

2.2.1

Recombinant Human Metallothionein 1a Constructs

The plasmid vectors for the recombinant peptides of human metallothionein isoform 1a
were constructed using the pET29a plasmid (Novagen/ EMD Biosciences, San Diego,
USA) at Cardiff University, Wales, UK and transformed into competent E. coli BL21
(DE3) pLysS cells (Novagen/EMD Biosciences) at the University of Western Ontario,
London, Canada (187, 188). The pET29a plasmid contains a kanamycin resistance gene
to select for cells that contain the plasmid with the recombinant protein sequence. The
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sequences of the DNA constructs were based on the sequence of the native protein, but
do contain minor sequence variations from that published by Richards et al. (189). The
recombinant β-rhMT, α-rhMT and βα-rhMT 1a proteins are composed of 38-residue, 41residue,

and

ATGGSCTCTG

72-residue

sequences,

SCKCKECKCN

respectively:
SCKKAAAA,

β-rhMT
α-rhMT

MGKAAAACSC
MGKAAAAC

CSCCPMSCAK CAQGCVCKGA SEKCSCCKKA AAA, βα-rhMT MGKAAAACSC
ATGGSCTCTG SCKCKECKCN SCKKAAAACC SCCPMSCAKC AQGCVCKGAS
EKCSCCKKAA AA. The expression system includes an N-terminal S-peptide tag on
the N-terminus of each protein (MKETAAAKFE RQHMDSPDLG TLVPRGS), which
was originally used as an affinity tag for purification, but is now retained simply for
stability purposes. The transformed cells were grown in LB broth with cadmium and
kanamycin until the absorbance at 600 nm was approximately 0.6. The cells were then
re-suspended in 1 mL solutions of 50% (v/v) LB medium and 50% (v/v) glycerol and
stored long-term at -80 °C (188).

2.2.2

Protein Expression

A portion of the glycerol stock solutions of transformed E. coli cells was streaked on LB
agar containing 50 µg/mL of kanamycin and 50 µM of CdSO4 (Fisher Scientific) and
incubated at 37°C overnight. Large preparations (4 × 1 L) were produced by inoculating
the transformed cells from the agar plates equally into four Fernbach flasks containing 1
L of LB liquid cell culture broth with 50 µg/mL kanamycin and 50 µM CdSO4.
Cadmium was added to both the agar plates and the initial liquid culture to protect any
MT expressed at a basal level during cell growth. The culture flasks were stirred at 175
rpm on a cell shaker incubated at 37°C to induce rapid growth of the E. coli cells until the
solution reached an absorbance of approximately 0.6 at 600 nm (Varian Cary® 500). At
an OD600 of 0.6, the E. coli cells are believed to be in the log-phase of their growth cycle.
Protein expression was then induced by the addition of 700 µM (final concentration)
isopropyl-β-D-thiogalactoside (IPTG) and the CdSO4 concentration was increased to 250
µM to stabilize the nascent MT. Incubation and shaking continued for four hours, at
which point the cells were harvested by centrifugation at 6000 rpm for 15 min at 4°C
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(Avanti J-series centrifuge; JLA-8.1000 rotor; Beckman-Coulter), re-suspended in 35 mL
of 10 mM tris(hydroxymethyl)aminomethane (Tris) at pH 7.4, and stored at -80°C.

2.2.3

Protein Purification

Semi-thawed cells were lysed using a cell disruptor (Constant Systems Ltd.) and
centrifuged at 13 000 rpm and 4°C for 1 h (Avanti J-series centrifuge; JA-25.50 rotor;
Beckman-Coulter) to separate the soluble proteins in the supernatant from the cellular
debris. After isolation of soluble proteins, all manipulations of the protein solutions were
completed on ice and with minimal oxygen exposure. The protein solution was gravity
filtered and rhMT 1a was isolated by tandem cation exchange columns (HiTrapTM SP
SepharoseTM HP cartridges; Amersham Biosciences/GE Healthcare) coupled to an LC
pump (Dionex/ Thermo Scientific). The two buffers required for the ion exchange
column were 10 mM Tris-HCl (pH 7.4; washing buffer) and 10 mM Tris-HCl with 1 M
NaCl (pH 7.4; elution buffer). Eluent from the column passed through a quartz flow-cell
and was monitored by UV absorption spectroscopy (Varian Cary® 50, Agilent
Technologies) using the Cary® WinUV Scanning Kinetics software to scan continuously
over the 200-300 nm region. The washing buffer was used to remove any molecules that
adhered weakly to the column; the column was washed with approximately fifteen
column volumes (~150 mL) at 2.5 mL/min or until the absorbance returned to the
baseline. The elution buffer was used to elute the bound MT, again at a flow rate of 2.5
mL/min, using a gradient of increasing salt concentration up to 25% (v/v) elution buffer
and 75% (v/v) washing buffer.
Fractions with the distinctive UV absorption at 250 nm (corresponding to the ligand-tometal charge transfer transition of the S-Cd bonds in the metal-thiolate clusters) (Figure
2.1), which were assumed to contain rhMT 1a, were pooled and concentrated to
approximately 10 mL using a stirred Ultrafiltration Cell with a 1000 Da cut-off
membrane (Amicon Bioseparations/ Millipore) and pressure from a nitrogen gas line.
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Figure 2.1. The UV absorption spectra of apo-rhMT 1a and Cd7-rhMT 1a. The apoprotein is shown in green and the holo-protein is shown in blue.

32

2.2.4

Cleavage of the N-terminal S-tag

Removal of the S-tag was achieved using a thrombin enzyme (Thrombin CleanCleaveTM
Kit, Sigma).

Thrombin is a serine protease that cleaves polypeptides at a specific

recognition sequence (X-X-Pro-Arg/Lys•Y-Y, where X is a hydrophobic residue, Y is a
non-acidic residue, and the • represents the bond that is cleaved). For the recombinant
MT fusion protein detailed above, the sequence recognized by the cleavage enzyme is
Leu-Val-Pro-Arg•Gly-Ser. In the kit, the thrombin is immobilized on agarose beads and
stored at -20°C as a mixture of 50% (v/v) glycerol and 50% (v/v) 20 mM Tris-HCl (pH
8.0; storage solution). The resin was washed in a solution of 50% (v/v) 50 mM Tris-HCl
(pH 8.0) and 50% (v/v) 10 mM CaCl2 (1× cleavage buffer) and centrifuged at 2500 rpm
for 5 min (Eppendorf centrifuge 5418). The supernatant was removed and the thrombincoated beads were re-suspended in 90% (v/v) 500 mM Tris-HCl (pH 8.0) and 10% (v/v)
100 mM CaCl2 (10× cleavage buffer). The concentrated protein solution was added to
the thrombin beads under argon gas and stirred constantly overnight at 4°C.

The

thrombin beads were then recovered from the protein solution by centrifugation, washed
in 1× cleavage buffer and an equal volume of 50 mM Tris-HCl (pH 8) with 500 mM
NaCl, and re-suspended in the storage solution for preservation at -20°C.
The supernatant containing the cleaved protein was collected and desalted using a size
exclusion column (SephadexTM G-25) pre-equilibrated with a 10 mM Tris buffer (pH
7.4), and the UV absorbance between 200 and 300 nm. The recombinant β-MT, α-MT
and βα-MT protein fractions were separated from the S-tag using cation exchange with
the same washing and elution buffers as above, and concentrated to approximately 10 mL
using the Ultrafiltration Cell system. The S-tag peptide bound weakly to the cation
exchange column and eluted during washing; the recombinant β-MT, α-MT and βα-MT
proteins eluted from the column with approximately 15% (v/v) elution buffer.
At this point, the purified Cd3-β-rhMT, Cd4-α-rhMT and Cd7-βα-rhMT 1a protein
solutions were separated into 1 mL fractions and stored at -20°C until experimentation
with ESI MS. Rigorous evacuation followed by argon saturation of all buffers, reagents,
and protein solutions was used to impede oxidation of the cysteine residues. Low
temperatures were used to aid in preventing protein degradation.
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2.2.5

Preparation of Apo-Metallothionein

Apo-metallothionein was prepared by adding 200 µL concentrated HCl to a thawed 1 mL
sample of purified Cd3-β-rhMT, Cd4-α-rhMT or Cd7-βα-rhMT 1a to demetallate the
protein, followed by buffer exchange on a size exclusion column (SephadexTM G-25) at
4°C using formic acid at pH 2.7 (in >16 MΩ cm deionized water; Barnstead Nanopure
Infinity). Low pH conditions cause denaturation and loss of the metal ions bound to MT,
and size exclusion chromatography separates the metals from the protein. This method
simultaneously demetallates and desalts the solution. Because MT is devoid of aromatic
amino acids, the metal-free protein fractions were detected using UV absorption at 220
nm (corresponds to electronic transitions from the polypeptide backbone) (Figure 2.1). A
formic acid buffer (pH 2.7) was chosen for analysis to aid in the stability of the metalfree protein and slow down oxidation of the many cysteine residues, as well as ensure MS
compatibility.

2.2.6

Protein Quantification

Protein concentrations were determined by re-metallation of a portion of the apo-rhMT
with Cd2+. The concentration of Cd-rhMT was then determined by UV absorption
spectroscopy using absorbance at 250 nm, which corresponds to the ligand-to-metal
charge transfer transition generated by cadmium-bound MT (Ɛβ= 36 000 M-1cm-1 (186,
190); Ɛα= 45 000 M-1cm-1 (186); Ɛβα= 89 000 M-1cm-1 (186, 191)).

2.3 ESI MS Procedures
2.3.1

Solution Conditions

Protein solutions were prepared in formic acid at pH 2.7 (in <16 MΩ cm deionized
water). Final ESI MS solutions were adjusted to biological pH (approximately pH 7.4)
using concentrated ammonium hydroxide. The solutions were thoroughly de-aerated by
evacuation and saturated with argon to remove the majority of the oxygen and to prevent
oxidation of the apo-protein when the pH was raised. All protein solutions remained
sealed and on ice during experimentation to help prevent oxidation and protein
degradation.
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2.3.2

Instrument Settings and Calibration

Mass spectra were collected on an electrospray ionization time-of-flight mass
spectrometer (micOTOF-II, Bruker Daltonics) in the positive ion mode. NaI was used as
the mass calibrant. The scan conditions for the spectrometer were as follows: end plate
offset -500V; capillary +4200 V; nebulizer 2.0 bar; dry gas flow 8.0 L/min; dry
temperature 80°C; capillary exit 180 V; skimmer 1 22.0 V; hexapole 1 22.5 V; hexapole
RF 600 Vpp; skimmer 2 22 V; lens 1 transfer 88 µs; and lens 1 pre pulse storage 23 µs.
The range was 500.0 - 3000.0 m/z, averaging 2 × 0.5 Hz. Spectra were collected and
deconvoluted using the Bruker Compass Data Analysis software package.

2.3.3

Metallation with Zn2+

Zinc sulfate (10 mM; Caledon Laboratory Chemicals) was prepared in <16 MΩ cm
deionized water; all molar equivalents were determined using atomic absorption
spectrometry (Varian AA240).

For competition experiments, protein solutions were

prepared such that all proteins in a sample were present in equimolar concentrations.
Spectra of apo-proteins were recorded to ensure that the expected masses were observed
within a small amount of error (±0.1%). Increasing amounts of Zn2+ were then added to
protein solutions in molar equivalents using a syringe to inject the ZnSO4 solution
through the septum cap and lessen the exposure to oxygen.

2.4 Molecular Modelling
Molecular mechanics (MM3) and molecular dynamics (MD) calculations are often used
in protein studies to visualize or predict the folding of a protein, the relative locations of
the amino acids to one another, and/ or the movement of the protein in solution (192).
Modelling parameters and sequence information have been previously described for
studies of rhMT 1a (126). MM3 and MD calculations, parameterized using the modified
force field described by Chan et al. (193) and using the dielectric constant for water
(78.4), were carried out to obtain the minimum-energy structures of apo-βα-rhMT 1a, and
Znn-βα-rhMT 1a (where n = 1 to 7) (Subsection 3.2.2, Figure 3.16). The original Cd7-βαrhMT 1a was modified to produce molecular models for the intermediate species in the
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metallation reactions with Zn2+ (185). Molecular modelling calculations, using the same
parameters referenced above, were conducted using Scigress (Version 3.0.0, Fujitsu
Poland Ltd.) operating on Intel® Core™ i7 PCs with 8 GB RAM. Each structure was
energy minimized using the MM3 calculation followed by the MD simulation at 300 K
for 5000 ps.
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3

Results and Discussion
3.2 Non-Cooperative Zn2+ Binding

Since mammalian metallothionein (MT) was initially isolated in 1957 (91), the exact
mechanism of the metallation of MT has remained a mystery.

The established

hypothesis, mainly developed from NMR spectroscopy, is that MT metallates in a
cooperative ‘all or nothing’ fashion (183). For proteins that bind their substrates
cooperatively, the only considerable species are the substrate-free or fully saturated
protein because intermediates would likely be too unstable to take part in cellular
chemistry.
Metallation of MT has been proposed to occur via a domain-specific cooperative
mechanism, where the first four Cd2+ are exclusively bound by the α-domain, and the
following three Cd2+ are bound by the β-domain. In this cooperative mechanism of
metallation, the only stable species that are expected to be observed are the apo- and
holo-protein, and possibly a Cd4-species. The apo-protein, with twenty free cysteine
thiols, would be highly susceptible to oxidation and any partially metallated forms would
likely be unstable and almost as vulnerable to oxidation.
A number of acid-induced demetallation studies of MT have suggested that demetallation
of the two clustered binding domains occurs as a two-step cooperative process in which
each individual step results in the complete loss of one of the clusters (177, 185, 194,
195). This model suggests that acid-induced loss of a single metal ion destabilizes the
cluster and promotes complete metal ion dissociation. In contrast to this theory are
studies that suggest that holo-MT is capable of donating several of its metal ions to Zn2+
depleted apo-enzymes without complete demetallation (196).

In addition, oxidizing

agents have been shown to release some of the Zn2+ bound to MT (197).
Understanding the correct mechanism of MT metallation profoundly impacts our
understanding of the stability of the clustered holo-protein, as well as any partially
metallated species, and their role in cellular chemistry; however, delineation of the
mechanism depends entirely on the ability to distinguish partially metallated
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intermediates.

To further investigate the mechanism of metallation, Stillman and

colleagues have previously used the discriminating power of ESI MS to demonstrate the
stability of partially metallated forms of MT 1 with Cu+ (172, 178), Ag+ (172), Cd2+ (120,
176), As3+ (111, 173), and Bi3+ (146). ESI MS measures the mass-to-charge ratio of all
species in solution; deconvolution of the mass spectra provides the stoichiometric ratios
of the various metallated species. Stable partially metallated MT was observed during
ESI MS metallation experiments with Cd2+, Bi3+, and As3+, supporting a non-cooperative
mechanism for binding of these metals (111, 120, 146, 173, 175, 176, 198).
Many proteins do not show any form of cooperativity in substrate binding. In these
proteins, substrate-binding events are independent and are described as non-cooperative.
If Zn2+ binding to MT is non-cooperative, the KF is expected to depend on the number of
available binding sites and therefore, the binding affinity is expected to decrease
statistically with each successive binding event (140, 199). In this case, with limiting
amounts of metal ions, not all metal binding sites would be occupied and a number of
partially metallated species are expected. The kinetic data of Ngu et al. (111, 173, 174,
200) provided clear evidence for non-cooperative metallation with As3+; the series of rate
constants determined from time-dependent As-metallation diminished for each successive
metal bound up to the sixth, and final, As3+.

3.2.1

Metallation of the β-domain with Zn2+

With confirmation that metallation of MT with Cd2+ and As3+ follows a non-cooperative
mechanism it is important to establish the binding mechanism for essential metals, such
as Zn2+ and Cu+. A clearer understanding of the metallation mechanism of MT with Zn2+
and Cu+ will allow for a much better understanding of the role MT plays as a
metallochaperone in the homeostasis of these metals.
The mass spectral data recorded during the metallation of apo-β-rhMT with Zn2+ clearly
show that the stepwise Zn2+ metallation of apo-β-rhMT leads to the formation of partially
metallated species (Zn1- and Zn2-β-rhMT) at sub-stoichiometric equivalents (< 3) of Zn2+
(Figure 3.1). Complete metallation occurs when approximately 3.5 equivalents of Zn2+
per β-rhMT were added to the solution. Complete metallation was expected to occur
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Figure 3.1. Mass spectra recorded during the titration of apo-β-rhMT 1a with Zn2+.
Spectra were recorded as aliquots of 7.3 mM ZnSO4 were added to a 29.2 µM solution of
apo-β-rhMT 1a (pH 9.2). (A-E) Charge state data (left) and deconvoluted data (right)
were recorded at molar equivalents of 0.1, 1.7, 2.6, 3.3, and 3.5 of Zn2+. Metallation in
excess of Zn3-β-rhMT is a result of non-specific adducts. Reprinted with permission
from Sutherland, D. E. K., Summers, K. L., and Stillman, M. J. (2012) Noncooperative
metalation of metallothionein 1a and its isolated domains, Biochemistry 51: 6690-6700.
© 2012 American Chemical Society.
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after exactly 3 Zn2+ were added to β-rhMT; however, the discrepancy in the equivalents
needed for complete metallation may be attributed to slight errors in the estimation of the
initial metal-free protein concentration, as well as to the formation of low concentrations
of Zn(OH)2.
It is clear that the most abundant metallated species is a direct result of the number of
equivalents of Zn2+ added to the solution. When 1.7 stoichiometric equivalents of Zn2+
are added to apo-β-rhMT, the dominant species is Zn1-β-rhMT (Figure 3.1 B), while at
2.6 equivalents of Zn2+ the two most abundant species are partially metallated Zn2-βrhMT and fully metallated Zn3-β-rhMT (Figure 3.1 C). The deconvoluted spectra can be
used as approximations of the actual metal ion distribution in solution because the
ionization potential of MT, and its isolated domains, is similar for all metallation states
(from apo-MT to fully metallated MT) (111, 173, 174, 200).
The relative abundance of each metallated β-rhMT species clearly demonstrates that
partial metallation occurs and therefore provides support for the hypothesis that
metallation occurs in a non-cooperative manner – at least for the N-terminal domain. At
each equivalent of Zn2+, with the exception of the beginning and end of the titration, the
β-rhMT exists as a mixture of metallated states. At low equivalents of Zn2+ partially
metallated species are most abundant (although the apo-protein is also present), while at
higher equivalents of Zn2+ the fully metallated β-rhMT is most abundant. The linear
progression of the metallation from apo-β-rhMT to Zn3-β-rhMT further supports a noncooperative mechanism, where the declining affinity of Zn2+ for β-rhMT is directly
related to the number of available metal-binding sites (Figure 3.2).

3.2.2

Metallation of the α-domain with Zn2+

From the mass spectra recorded during the stepwise metallation of apo-α-rhMT with
Zn2+, it is evident that metallation leads to the formation of partially metallated species
(Zn1-, Zn2-, and Zn3-α-rhMT) at sub-stoichiometric equivalents (< 4) of Zn2+ (Figure 3.3),
similar to Zn2+ metallation of the β-domain. The dominant metallation state is again a
direct result of the number of equivalents of Zn2+ added to solution.

When 2.2

stoichiometric equivalents of Zn2+ are added to apo-α-rhMT, the dominant species is Zn1-

40

Figure 3.2 Contour and bar graphs of the metallation of β-rhMT 1a as a function of
Zn2+ added. (A) A top-down view of metallation, showing the linear progression from
apo-β-rhMT to Zn3-β-rhMT as a function of Zn2+ added to the solution (100% abundance
is shown in red and 0% abundance is dark blue). (B) A bar graph of metallation, showing
the relative abundance of each species as a function of Zn2+ added to the solution. Colour
code: apo-β-rhMT is red; Zn1-β-rhMT is green; Zn2-β-rhMT is dark blue; Zn3-β-rhMT is
light blue. Plots are based upon the deconvoluted mass spectra in Figure 3.1. Reprinted
with permission from Sutherland, D. E. K., Summers, K. L., and Stillman, M. J. (2012)
Noncooperative metalation of metallothionein 1a and its isolated domains, Biochemistry
51: 6690-6700. © 2012 American Chemical Society.
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Figure 3.3. Mass spectra recorded during the titration of apo-α-rhMT 1a with Zn2+.
Spectra were recorded as aliquots of 7.3 mM ZnSO4 were titrated into a 34.1 µM solution
of apo-α-rhMT 1a (pH 9.5). (A-E) Charge state spectra (left) and deconvoluted spectra
(right) of α-rhMT were recorded at Zn2+ molar equivalents of 0.4, 2.2, 3.7, 3.9, and 4.1.
Reprinted with permission from Sutherland, D. E. K., Summers, K. L., and Stillman, M.
J. (2012) Noncooperative metalation of metallothionein 1a and its isolated domains,
Biochemistry 51: 6690-6700. © 2012 American Chemical Society.

42

α-rhMT (Figure 3.3 B), while at 3.7 and 3.9 equivalents of Zn2+ the dominant species are
Zn2- and Zn3-α-rhMT, respectively (Figure 3.3 C and D).

Complete metallation is

observed at 4.1 equivalents of Zn2+ added to solution; however, there is still a relatively
small amount (~23% of the total) of Zn3-α-rhMT. Complete metallation was expected to
occur when four Zn2+ were added to apo-α-rhMT, but similar to the situation with the βdomain, analytical errors in concentrations and competitive formation of Zn(OH)2 may
impact the accuracy of the specified equivalents.
The relative abundance of each metallated α-rhMT species clearly demonstrates the
stability of partially metallated species and thus provides evidence that metallation occurs
in a non-cooperative manner for the C-terminal domain as well (Figure 3.4). At each
equivalent of Zn2+ added, with the exception of the beginning and end of the titration, αrhMT also exists as a mixture of metallated states.

At low equivalents of Zn2+ a

distribution of partially metallated species are observed, while at excess equivalents (> 4)
of Zn2+ the fully metallated α-rhMT is most abundant. Interestingly, there is a slight
increase in the fraction of Zn2-α-rhMT before Zn3- and finally, Zn4-α-rhMT form (Figure
3.4). The linear progression of metallation from apo-α-rhMT to Zn4-α-rhMT provides
further evidence that metallation occurs in a non-cooperative manner, where the declining
affinity of Zn2+ for α-rhMT is also directly related to the number of available metalbinding sites.

3.2.1 Metallation of rhMT 1a with Zn2+
Similar to those for both the isolated β- and α-domains, mass spectra of the stepwise
metallation of apo-βα-rhMT detail the formation of partially metallated species (from
Zn1- to Zn6-βα-rhMT) at sub-stoichiometric equivalents (< 7) of Zn2+, confirming the
non-cooperative nature of the metallation reaction for the full human MT 1a (Figure 3.5).
Only after 5.9 equivalents of Zn2+ have been added to the solution does the holo-protein
begin to form (Figure 3.5 E). It is not until excess Zn2+ has been added that Zn7-βα-rhMT
becomes the most abundance species (Figure 3.5 F). Even at this point, there is still some
(~12% of the total) Zn5- and (~30%) Zn6-βα-rhMT remaining. Similar to the situation
with the individual domains, excess Zn2+ is required, likely because of slight errors in the
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Figure 3.4. Contour and bar graphs of the metallation of α-rhMT 1a as a function
of Zn2+ added. (A) A top-down view of metallation, showing the linear progression
from apo-α-rhMT to Zn4-α-rhMT as a function of Zn2+ added to solution (100%
abundance is shown in red and 0% abundance is shown in dark blue). (B) A side view of
metallation, showing the relative abundance of each species as a function of Zn2+ added.
Colour code: apo-α-rhMT is red; Zn1-α-rhMT is green; Zn2-α-rhMT is dark blue; Zn3-αrhMT is light blue; Zn4-α-rhMT is purple. Plots are based on the deconvoluted data in
Figure 3.3. Reprinted with permission from Sutherland, D. E. K., Summers, K. L., and
Stillman, M. J. (2012) Noncooperative metalation of metallothionein 1a and its isolated
domains, Biochemistry 51: 6690-6700. © 2012 American Chemical Society.
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Figure 3.5. Mass spectra recorded during the titration of apo-βα-rhMT 1a with
Zn2+. Spectra were recorded as aliquots of 7.3 mM ZnSO4 were titrated into a 29.2 µM
solution of apo-βα-rhMT 1a (pH 9.1). (A-F) Charge states of βα-rhMT (left) and
deconvoluted data (right) were recorded at Zn2+ molar equivalents of 0.9, 2.7, 3.7, 4.8,
5.9, and 8.4. Metallation in excess of Zn7-βα-rhMT is a result of non-specific adducts.
Reprinted with permission from Sutherland, D. E. K., Summers, K. L., and Stillman, M.
J. (2012) Noncooperative metalation of metallothionein 1a and its isolated domains,
Biochemistry 51: 6690-6700. © 2012 American Chemical Society.
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estimation of the apo-protein concentration and the formation of trace amounts of
competitive Zn(OH)2 due to the high pH of the solution. Also similar to the Zn2+ titration
with the individual domains, the number of equivalents of Zn2+ added dictates the
dominant metallation state present in the full protein at each step in the titration. For
example, after the addition of 3.7 equivalents of Zn2+, the most abundant species was
Zn4-βα-rhMT (Figure 3.5 C). Likewise, when 5.9 equivalents of Zn2+ were added, Zn6βα-rhMT was the most abundant species (Figure 3.5 E).
The relative abundance of each metallated βα-rhMT species demonstrates that the
partially metallated species are stable and that metallation in human metallothionein 1a is
non-cooperative (Figure 3.6). At each equivalent of Zn2+, with the possible exception of
the beginning and end of the titration, βα-rhMT exists as a mixture of at least three
metallated states.

At low equivalents of Zn2+ only partially metallated species are

observed, while at excess equivalents (> 7) of Zn2+ only the fully metallated βα-rhMT is
expected to be observed. Interestingly, one partially metallated species appears more
prominent than the other intermediates; the Zn5-βα-rhMT species occupies a greater
fraction of the distribution than expected (Figure 3.5 D; also starred in Figure 3.6 B).
The linear progression of metallation from apo-βα-rhMT to Zn7-βα-rhMT demonstrates
that metallation occurs in a non-cooperative manner, where the affinity of Zn2+ for βαrhMT is directly related to the number of available metal-binding sites.

3.2.1 A Stable Zn5-βα-rhMT Intermediate
The increased stability of the intermediate Zn5-βα-rhMT species may be of particular
significance in the metallation pathway of human metallothionein 1a.

After 4.8

equivalents of Zn2+ have been added to the solution of apo-βα-rhMT, the spectra are
simplified with Zn5-, and small amounts of Zn4-βα-rhMT (~29%) and Zn6-βα-rhMT
(~14%) present (Figures 3.5 D and 3.6 B). This simplification of the distribution of
species suggests that the binding constant (KF) of Zn6-βα-rhMT is significantly lower
than that of Zn5-βα-rhMT and that therefore, excess Zn2+ must be added for MT to bind
the sixth Zn2+.
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Figure 3.6. Contour and bar graphs of the metallation of βα-rhMT 1a as a function
of Zn2+ added. (A) A top-down view of metallation, showing the linear progression
from apo-βα-rhMT to Zn7-βα-rhMT as a function of Zn2+ added (100% abundance shown
in red and 0% abundance shown in dark blue). (B) A side view of metallation, showing
the relative abundance of each species as a function of Zn2+ added. Colour code: apo-βαrhMT is red; Zn1-βα-rhMT is green; Zn2-βα-rhMT is dark blue; Zn3-βα-rhMT is light
blue; Zn4-βα-rhMT is light purple; Zn5-βα-rhMT is orange; Zn6-βα-rhMT is violet; Zn7βα-rhMT is indigo. The star indicates the increased fraction of Zn5-βα-rhMT. Graphs are
based upon the deconvoluted data in Figure 3.5. Reprinted with permission from
Sutherland, D. E. K., Summers, K. L., and Stillman, M. J. (2012) Noncooperative
metalation of metallothionein 1a and its isolated domains, Biochemistry 51: 6690-6700.
© 2012 American Chemical Society.
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The exact reason for this decrease in binding affinity is not clear from these data. I
hypothesize that after the addition of five Zn2+, each of the Zn2+ are coordinated to four
terminal cysteine residues and that binding of the sixth Zn2+ requires a structural
rearrangement of these residues to form the first part of the expected two-domain
structure. Previous studies have provided evidence to support the hypothesis that metals
are initially coordinated to terminal cysteines before clustering takes place. However,
these studies investigated only metals for which spectroscopic probes are available – not
Zn2+. Several authors using a range of techniques, including
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Cd-NMR, Co-EPR and

CD spectroscopies, to monitor metallation titrations have concluded that the initial
metallation of MT must occur through exclusively terminal cysteine residues, after which
cluster formation leads to bridging interactions (183, 201, 202).
From the results of a Cd2+ titration with rabbit liver MT 2 using NMR spectroscopy, it
was proposed that the β-domain was metallated only after the complete saturation of the
α-domain (183).

The authors fail to comment on a broad featureless peak at

approximately 688 ppm that could be a Cd5-MT species; the exclusively terminal
coordination of Cd2+ to cysteine would cause significant fluctionality in the structure.
Until their experiment is repeated using mass spectrometry to confirm the metal
speciation as a function of metal loading, a domain specific, cooperative mechanism – at
the high concentrations required for NMR spectroscopy – cannot be ruled out for Cd2+
binding to MT 2. At much lower concentrations (~10 µM), human MT 1a has been
reported to bind Cd2+ non-cooperatively (120, 176).
An alternative hypothesis would be that a single Zn2+ binds in the β-domain and four
Zn2+ bind cooperatively in the α-domain. While reports on spectroscopic data have been
interpreted in terms of a domain-specific, cooperative mechanism (resulting in the
complete saturation of one domain before the other), thermodynamically, terminally
bound thiols exhibit shorter bond lengths than bridged thiols and are, therefore, more
energetically favourable. A complex involving twenty terminal S-Zn2+ bonds in a chain
of five ZnCys4 units would be thermodynamically more favourable than a Zn4Cys11
cluster, a single ZnCys4 unit, and five available cysteines. In addition, the cysteines
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would be protected from oxidation in a structure with all-terminal coordination as
opposed to the domain-specific mechanism.

3.2.2

Simulating Metal Binding Mechanisms

The Zn2+ metallation properties of the isolated fragments and full protein were
determined using sensitive, soft ESI MS methods (Figures 3.1 – 3.6). By analyzing the
distribution of metallated states for both the rhMT and its isolated domains, it is evident
that metallation occurs in a linear, step-wise fashion, which indicates that each Zn2+ binds
non-cooperatively (Figures 3.2, 3.4 and 3.6). Contrasting this mechanism is the ESI MS
work of Gehrig et al. (92), which was interpreted to argue that Zn2+ metallation of MT 2
proceeds in a cooperative manner.
The experimental mass spectra of the metallation of MT 1a with Zn2+ (from Figure 3.1,
3.3, and 3.5) were plotted in terms of the 'life' of each Znn-MT species (where n=0-7) to
further demonstrate that MT metallates via a non-cooperative mechanism (Figure 3.7 A,
B, and C). This unique depiction of the individual metallated species highlights the
distribution of species present at each point in the titration. Techniques that cannot
discriminate between the various metallated species simply average the data from several
species with different metallated states and, therefore, cannot provide the same level of
information.
The stepwise metallation equations for α-, β-, and βα-rhMT 1a with Zn2+ are shown
below:
Equation 1: Metallation of the β-domain peptide
K

1#
apo " # " rhMT + Zn 2+ $ $
% Zn1 " # " rhMT

K

2#
Zn1 " # " rhMT + Zn 2+ $ $
% Zn 2 " # " rhMT

K

3#
Zn 2 " # " rhMT + Zn 2+ $ $
% Zn 3 " # " rhMT

!
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Figure 3.7. Experimental and theoretical data showing Zn2+ metallation through
different binding mechanisms. (A, B, C) Speciation during metallation of the β- and αdomains, and the full MT protein with Zn2+. (D, E, F) Simulation of ESI MS data using
non-cooperativity rules (declining Ks). (G, H, I) Simulation using weakly cooperative
binding rules (equal Ks). (J, K, L) Simulation using strongly cooperative binding rules
(increasing Ks). Each line corresponds to a different metallation state: Zn0(
), Zn1(
), Zn2(
), Zn3(
), Zn4(
), Zn5(
), Zn6(
) and Zn7(
).
Adapted from Biochemical and Biophysical Research Communications, 426, Sutherland,
D. E. K., Summers, K. L., and Stillman, M. J., Modeling the Zn2+ and Cd2+ metalation
mechanism in mammalian metallothionein 1a, 601-607. © 2012 with permission from
Elsevier.
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Equation 2: Metallation of the α-domain peptide
1#
apo " # " rhMT + Zn 2+ $K$
% Zn1 " # " rhMT
2#
Zn1 " # " rhMT + Zn 2+ $K$
% Zn 2 " # " rhMT
3#
Zn 2 " # " rhMT + Zn 2+ $K$
% Zn 3 " # " rhMT
4#
Zn 3 " # " rhMT + Zn 2+ $K$
$
% Zn 4 " # " rhMT

Equation 3: Metallation of the complete βα-rhMT 1 a

!

K

1 #$
apo " #$ " rhMT + Zn 2+ % %
%& Zn1 " #$ " rhMT

K

2 #$
Zn1 " #$ " rhMT + Zn 2+ % %
%& Zn 2 " #$ " rhMT

K

3 #$
Zn 2 " #$ " rhMT + Zn 2+ % %
%& Zn 3 " #$ " rhMT

K

4 #$
Zn 3 " #$ " rhMT + Zn 2+ % %
%& Zn 4 " #$ " rhMT

K

5 #$
Zn 4 " #$ " rhMT + Zn 2+ % %
%& Zn 5 " #$ " rhMT

K

6 #$
Zn 5 " #$ " rhMT + Zn 2+ % %
%& Zn 6 " #$ " rhMT

K

7 #$
Zn 6 " #$ " rhMT + Zn 2+ % %
%& Zn 7 " #$ " rhMT

This set of chemical equations represents the stepwise metallation of each protein where
!

the binding affinities are represented by an equilibrium constant Kn (where nβ= 1 to 3;
nα= 1 to 4; nβα= 1 to 7). When Zn2+ is added under equilibrium conditions, the resulting
products will depend on the relative Ks.
The experimental ESI MS data for Zn2+ metallation of human MT 1a (Figures 3.1, 3.3,
and 3.5) were compared to the predicted speciation from three mechanistic simulations
(Figure 3.7 D–L).

The theoretical metallation curves for a non-cooperative system

(K1>K2>K3…>Kn) (Figure 3.7 D, E, F), a weakly cooperative system (K1=K2=K3=…Kn)
(Figure 3.7 G, H, I), and a strongly cooperative system (K1<K2<K3…<Kn) (Figure 3.7 J,
K, L) were used to provide an unambiguous indication of the metallation mechanism
through a comparison of the simulation with the experimental ESI MS data. For MT, the
binding affinities are expected to decrease as the binding sites fill, resulting in a
distribution of metallated species. The maximum abundance of each metallated species
is therefore expected to be approximately equal because the metallation proceeds through
a series of bimolecular reactions (shown above).

In a weakly cooperative binding

mechanism, the maximum intensity of all intermediate species, except Zn1-MT, is
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suppressed leading to the formation of fully metallated MT after the addition of only four
equivalents of Zn2+ (Figure 3.7 G, H, I). This trend is further enhanced in the cooperative
mechanism of metallation, where the intermediate species are even further suppressed
and the fully metallated MT forms after the addition of only two equivalents of Zn2+
(Figure 3.7 J, K, L).
From these simulations (Figure 3.7 D–L), it is clear that if these proteins were metallated
in a cooperative manner, holo-MT should appear in the mass spectra after the first
equivalent of Zn2+ was added. The only abundant species would be the apo- and holoprotein; the partially metallated species would be present in low abundance or almost
nonexistent at each step in a titration with Zn2+. A comparison between the experimental
data and the modelled data provides strong evidence that metallation occurs via a noncooperative mechanism (Figure 3.7).
The simulation can also be used to calculate the actual distribution of metallated species,
similar to a mass spectrum, at each addition of Zn2+. The simulated deconvoluted mass
spectra of βα-rhMT for two additions of Zn2+ (0.9 and 5.9 equivalents), based on the
three mechanistic models, are easier to compare directly with experimental ESI MS data
(Figure 3.8). The two points chosen provide a clear differentiation between the three
mechanisms tested. In the non-cooperative mechanism, the dominant species is directly
related to the number of equivalents of Zn2+ added to the solution, so that at 0.9 eq. of
Zn2+ added, Zn1-βα-rhMT is the most abundant; but at 5.9 eq. of Zn2+, Zn6-βα-rhMT is
the most abundant (Figure 3.8 B). The weakly cooperative mechanism demonstrates an
initial metallation pattern similar to that of the non-cooperative mechanism; however,
when a higher amount of Zn2+ is added, there is a much higher proportion of the fully
metallated protein (Figure 3.8 C). As was expected, a cooperative mechanism favours
either the apo-protein (prior to the addition of sufficient metal) or the holo-protein, with
very low concentrations of partially metallated intermediates (Figure 3.8 D).
From the experimental mass spectra (Figures 3.1 – 3.6) and the simulations (Figures 3.7
and 3.8), it is clear that the mechanism of metallation of rhMT 1a with Zn2+ is noncooperative. The model data demonstrate that there are significant differences in the
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Figure 3.8. Experimental and simulated MS data for the metallation of apo-βαrhMT 1a with Zn2+. (A) Experimental MS data for βα-rhMT 1a with 0.9 and 5.9
equivalents of Zn2+. Simulated MS data based upon non-cooperative (B) weakly
cooperative (C) and cooperative (D) mechanisms. Adapted from Biochemical and
Biophysical Research Communications, 426, Sutherland, D. E. K., Summers, K. L., and
Stillman, M. J., Modeling the Zn2+ and Cd2+ metalation mechanism in mammalian
metallothionein 1a, 601-607. © 2012 with permission from Elsevier.
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metallation pattern of a cooperative and a non-cooperative mechanism and that ESI MS
data are sensitive to these differences.

3.2.3

A Non-Cooperative Metallation Mechanism for rhMT 1a

Understanding the role of MT as a metallochaperone relies upon an understanding of its
metallation properties, but the metallation properties of MT make the mechanistic study
of the protein difficult. The coordination environment for all bound metal ions is similar.
The affinity of the cysteinyl-thiolates for divalent metal ions (e.g., Zn2+ and Cd2+) is
extremely high – too high to monitor kinetically. Spectroscopic probes cannot readily
discriminate between the different metallated states of MT. As a result, the mechanism
of metallation of mammalian MT has been intensively debated. Different reports present
either a cooperative or non-cooperative mechanism of metallation in explanation of the
data. Recent ESI MS data have provided significant new information about the early
stages of metallation of metalloproteins (120, 168, 176, 203, 204), along with the
discovery of the ‘supermetallated’ (metallation in excess of traditional levels) forms of
MT (190, 191, 204).
In addition to the confusion regarding the mechanism, there has also been uncertainty as
to the exact species formed following the addition of sub-saturating numbers of metal
ions. Before metallation experiments were conducted using ESI MS, MT was often
assumed to be homogenously metallated, meaning that the addition of one equivalent of
M (the metal ion of interest) was interpreted as leading to the exclusive formation of M1MT, the addition of 2 equivalents of M resulted in precisely M2-MT, and so on up to
saturation. The metal distribution is represented by the ratio of the relative binding
constants (K7: K6: K5: K4: K3: K2: K1). Calculating the expected metal distribution in a
stepwise titration and comparing it with the experimental data allowed the ratio of the
relative binding affinities and consequently, the binding mechanism, to be determined.
Only ESI MS data provide the exact distribution of metallated species at each point,
allowing this comparison.
Initial studies of both the metallation and demetallation reactions of MT led to the
hypothesis that metallation occurred in a cooperative fashion. There are three important
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consequences of the cooperative mechanism. First, partially metallated forms would only
ever represent a very low fraction (only fully metallated and fully metal-free would
persist). Second, partially metallated forms would be unlikely to be available to play a
major role in cellular chemistry and third, oxidation of the protein would lead to
complete, cooperative demetallation of the protein.
Recent kinetic studies of As3+ metallation of hMT1 demonstrated conclusively that the
affinity of MT for As3+ is directly dependent upon the number of available metal binding
sites and that the specific rate constants for As3+ binding decline linearly as the number of
bound As3+ increases, forming a chain of up to six cysteine-coordinated AsCys3 units
(111, 173, 200). If As3+ binding was cooperative, the specific rate constants would
increase for each successive As3+ bound.
While the results presented above conclusively show that the mechanism of metallation
of MT with Zn2+ is non-cooperative, the possibility that these results may be isoform
specific cannot be ruled out. MT 1a metallates non-cooperatively with Cd2+, and As3+
(120, 173, 176), and as shown herein, also with Zn2+, but MT 2a is still believed to
metallate cooperatively with Zn2+, Cd2+ and Cu+ (92, 183, 205). Recently, significant
differences in the metallation chemistry of the MT isoforms have been noted. Both MT
1a and MT 3 are able to bind an eighth M2+ forming the ‘supermetallated’ M8-βα-rhMT
(where M2+ is Cd2+ for MT 1a and Zn2+ for MT 3; (191, 203)), while MT 2 is thus far
known to bind only seven M2+ ions forming M7-βα-rhMT (where M2+ is Zn2+ or Cd2+).
These results provide further evidence to support a specific cellular function for each MT
isoform.
Since the mechanism of metallation is non-cooperative for Zn2+, one of the most common
metals bound by MT in vivo, partially metallated species are presumably able to take part
in cellular chemistry. In fact, instances in which partially metallated forms of the protein
have been purified could represent the in vivo forms of the protein (206). In addition, MT
may now be described as able to impede oxidative stress in a dynamic way. Progressive
oxidation may lead to the sequential release of Zn2+ ions and eventually complete
oxidation of the protein. The released Zn2+ may then bind to MTF-1 and lead to an
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upregulation of genes for MT and other associated proteins, thus resisting oxidative stress
(207). The balance between the metallated MT and the metal free MT was thought to
mediate the redox chemistry of the cell (154, 208, 209); however, this view assumed a
cooperative binding mechanism for metallation of metallothionein with zinc.

It is

possible that the average metal load of MT is what actually dictates the oxidative
environment in a cell. DFT calculations of the reactivity of polynuclear zinc-thiolate
sites have shown the mononuclear ZnCys4 group to be more nucleophilic than either of
the two fully metallated Zn3Cys9- and Zn4Cys11-clusters (210). Given this information
and the work presented here, Zn5-MT should be able to take part in cellular chemistry as
a protective agent against oxidative stress even though it posesses no free thiol groups.

3.2.4

Summary

The results presented above demonstrate that Zn2+ metallation occurs in a noncooperative manner, similar to Cd2+ and As3+ (111, 120, 173, 176), and currently in
contrast to Cu+ (121). It is now clear that one of the two most significant metals in
metallothionein cellular chemistry metallates in a non-cooperative manner. There is a
prominent, stable Zn5-βα-rhMT species in the Zn2+ metallation pathway, which is
hypothesized to be composed of terminally coordinated Zn2+ distributed in a series of
ZnCys4 groups along the peptide chain. The transition from terminal to bridging Cys
would reduce the affinity of the protein for Zn2+ and enhance the stability of Zn5-βαrhMT. While domain specificity may exist, and Zn2+ may initially bind preferentially at
either the N-terminus (β-domain) or the C-terminus (α-domain), domain formation likely
occurs with the binding of the sixth Zn2+.

3.3 A Revised Structure of Holo-Metallothionein
The structure of metallated human metallothionein is thought to be that of a dumb-belllike structure in which the two domains, β and α, are separated by an amino acid linker
(as discussed in Section 1.4). This dumb-bell shape was first observed through the
crystal structure described from X-ray diffraction data on rat liver Cd5Zn2MT 2 (69, 114).
The structure of Zn7-MT has since been determined from 2D-1H NMR and is essentially
identical to that of Cd7-MT (117). X-ray (69, 114), Cd-NMR (69, 115, 117), XAFS (137,
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138, 193), and modelling methods (211) all agree that Cd7-MT is a tight, two-domain
structure dominated by Cd-thiolate cross-linking (94). The formation of the two metalthiolate clusters is believed to occur in a way that allows different metal binding and
stoichiometries in each domain. However, recent studies have provided evidence that
this two-domain structure may be only one step in the complex metallation pathway of
mammalian metallothionein (186, 191).
Metal binding in MT has been studied in a number of metallation, demetallation and
metal replacement experiments conducted under equilibrium and kinetic conditions (95,
140). In particular, previous studies of the metal binding properties of human MT 2 with
Zn2+ have shown a series of affinities that differ by four orders of magnitude (highest
affinity KF=1011.8, lowest affinity KF=107.7; (166)). This range of formation constants is
thought to allow MT to act as a robust metallochaperone capable of accepting Zn2+ in
cases of excess and donating Zn2+ in cases of deficiency. However, previous metallation
experiments, such as copper luminescence, often provide only an averaged measure of
metallation, not the exact speciation for all possible sites (118, 172). The discriminating
capability of ESI MS provides information about all species present and their respective
dynamic metallation states simultaneously.

Because Zn2+ binding to MT is non-

cooperative, the exact distribution at each step in the titration can be determined (186,
212).
Initially, the competition experiment between the two domains of human MT 1a
described below was designed to help determine which domain filled first.

The

hypothesis that the α-domain would metallate first was based on previous reports that
provided evidence for the saturation of the α-domain prior to the β-domain (183, 184),
and that the α-domain has one more Zn2+ binding site than the β-domain, although other
studies have indicated that the β-domain may metallate preferentially (145).
The following competition experiment between the two domains and the full protein was
designed to help determine the importance of the linker in the metallated structure. The
full protein was initially hypothesized to metallate prior to saturation of the domains
either because the two-domain structure arranged the Zn2+ binding sites in such a way
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that would allow superior metal binding, or because of the advantage of its additional
sites. However, in light of the non-cooperative nature of metallation and the increased
stability of Zn5-βα-rhMT (as determined in Section 3.1), it is not surprising that the data
suggested an entirely different interpretation.

3.3.1

Competitive Metallation of β- and α-rhMT 1a with Zn2+

From the mass spectra recorded during a competition experiment in which incrementally
added Zn2+ distributes between the β-domain (with three potential sites) and the αdomain (with four potential sites), it was evident that the α-domain did not bind all the
Zn2+ ahead of the β-domain (Figure 3.9). In this experiment, both domains were present
in equal concentration in the solution and thus the Zn2+ equivalents listed in Figure 3.9
are relative to the total protein concentration (β-domain + α-domain = 7 binding sites).
The charge state data are shown in Appendix A, Figure A.1.
The deconvoluted spectra show two distinct sets of peaks, which correspond to the
different masses of the β and α fragments (Figure 3.9). The data readily show the domain
preference for each added Zn2+; because there are seven binding constants in total, Zn2+
binding will be directed by the largest KF. The fractional distribution of Zn2+ between the
domains changes drastically as Zn2+ loading increases.
The average metallation of the fragments (based on the data in Figure 3.9) gives a clearer
picture of the Zn2+ distribution as increasing molar equivalents of Zn2+ were added
(Figure 3.10). Between 0 and approximately 4 molar equivalents of Zn2+ added, the βdomain binds a greater fraction of the Zn2+. After approximately 5 equivalents of Zn2+
were added, the α-domain binds a greater fraction – likely because it still has two sites
available. The β-domain clearly binds a greater fraction of the available Zn2+ up to Zn2β-rhMT. The lines representing β-rhMT and α-rhMT crossover when β-rhMT has bound
two Zn2+, probably because the α-domain now has an advantage with two remaining sites
compared with the single remaining site in β-rhMT (Figure 3.10) (111).
Simulating the competition experiment allows the proposed mechanism to be tested. The
experimental data for Zn2+ metallation of apo-β-rhMT and apo-α-rhMT (split into two
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Figure 3.9. Deconvoluted mass spectra recorded during the competitive titration of
β- and α-rhMT with Zn2+. (A-F) Aliquots of 8.3 mM ZnSO4 were added to the 29.2
µM apo-β- and apo-α-rhMT (pH 9.2) solution at molar equivalents of 0.4, 2.1, 3.5, 5.4,
7.6, and 8.0. The most intense species for both the β- and α-domain have been
normalized to 100% relative abundance; Zn2+ adducts are indicated by a star. The raw
m/z data can be found in Appendix A, Figure A.1. Reprinted with permission from
Summers, K. L., Sutherland, D. E. K., and Stillman, M. J. (2013) Single domain
metallothioneins: Evidence for the onset of clustered metal binding domains,
Biochemistry 52: 2461-2471. © 2013 American Chemical Society.
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Figure 3.10. The average metallation of β- and α-rhMT 1a as a function of Zn2+
added. The β- (
) and α-domains (
) are present in equal concentrations. The
plotted data were calculated from the spectra in Figure 3.9. Reprinted with permission
from Summers, K. L., Sutherland, D. E. K., and Stillman, M. J. (2013) Single domain
metallothioneins: Evidence for the onset of clustered metal binding domains,
Biochemistry 52: 2461-2471. © 2013 American Chemical Society.
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to show the relative Zn2+ binding for each domain) were compared with the simulation,
which uses seven diminishing KFs to represent the seven total sites in the β- and αdomains (Figure 3.11). The KF values were determined from the three-way competition
experiment involving the two domains and the full protein (described in 3.2.2 and Figures
3.12 – 3.14). It is striking that the KF model strongly mirrors the experimental data, with
the β-domain initially binding in preference to the α-domain because the KF values of the
first two Zn2+ binding sites in β-rhMT are higher.

3.3.2

Competitive Metallation of β-, α-, and βα-rhMT 1a with
Zn2+

When all three species (β-, α- and βα-rhMT) are mixed, they compete for added Zn2+, but
this time with fourteen binding sites that have different – but clearly very similar – KF
values. The experimental ESI MS data of this mixture containing the apo-β- and apo-αdomains, as well as the full apo-βα-protein, are even more surprising than the competition
experiment between the two domains with Zn2+ (Figure 3.12). The raw MS data are
complicated because the charge states for the two domain peptides and the full protein at
each metallated state overlap in the mass spectrum (Appendix A, Figure A.2). More
information can be extracted from the deconvoluted mass spectra (Figure 3.12). By
plotting the proportion of Zn2+ bound by each protein (while in equilibrium with the other
two species) up to full saturation of the proteins, the ‘life’ of the intermediate Zn2+
species formed as Zn2+ was added becomes more obvious (Figure 3.13). The average
Zn2+ bound by each protein can be readily determined by plotting the average metal
loading of each species as a function of added Zn2+ during competition (Figure 3.14).
The experimental data show that apo-βα-rhMT dominates Zn2+ binding up to the point
where 6.4 equivalents of Zn2+ have been added (Figure 3.12 C). This is clearer from a
comparison of the metallated species in solution (Figure 3.13 A, C, E); Zn3 and Zn4 have
formed in the full βα protein, but only Zn1 and Zn2 have formed in the isolated domains
after the addition of 6.4 equivalents of Zn2+. If the binding constants were equal, the Zn2+
would be distributed evenly between the three proteins (like in the weakly cooperative
mechanism described in Subsection 3.15).

The plots in Figure 3.13 (A, C, E)
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Figure 3.11. Stepwise metallation of apo-β-rhMT and apo-α-rhMT in competition
for added Zn2+. The metallation values for the β-domain (A) and the α-domain (C) were
calculated from the MS data in Figure 3.9. Simulations of the metallation of the βdomain (B) and the α-domain (D) used log10(KF) values of 12.7, 12.4, and 12.0 for the βdomain, and 12.6, 12.3, 11.8, and 11.5 for the α-domain. Each line corresponds to a
different metallation state: Zn0 (
), Zn1 (
), Zn2 (
), Zn3 (
), and Zn4 (
). Reprinted with permission from Summers, K. L., Sutherland, D. E. K., and
Stillman, M. J. (2013) Single domain metallothioneins: Evidence for the onset of
clustered metal binding domains, Biochemistry 52: 2461-2471. © 2013 American
Chemical Society.
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Figure 3.12. Deconvoluted mass spectra for the competitive titration of β-, α-, and
βα-rhMT with Zn2+. (A-F) Aliquots of 7.3 mM ZnSO4 were added to a solution
containing equimolar concentrations (29.9 µM each) of apo-β-, apo-α-, and apo-βα-rhMT
(pH 7.8) at molar equivalents of 1.8, 4.6, 6.4, 9.3, 10.3 and 12.5. The most intense
species for β-, α- and βα-rhMT have been normalized to 100% relative abundance. The
titration stopped prior to 14 equivalents because of the noise from the high ZnSO4
concentration. The raw m/z data are shown in Appendix A, Figure A.2. Reprinted with
permission from Summers, K. L., Sutherland, D. E. K., and Stillman, M. J. (2013) Single
domain metallothioneins: Evidence for the onset of clustered metal binding domains,
Biochemistry 52: 2461-2471. © 2013 American Chemical Society.
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Figure 3.13. The stepwise metallation of apo-β-rhMT, apo-α-rhMT, and apo-βαrhMT while in competition for added Zn2+. The experimental data for the β- (A) and
α-domains (C), and the full βα-rhMT (E) were calculated from the MS data shown in
Figure 3.12. The simulation of the metallation of the isolated domains (B, D) and the full
MT protein (F) used log10(KF) values of 12.7, 12.4 and 12.0 for the β-domain, 12.6, 12.3,
11.8 and 11.5 for the α-domain, and 13.3, 13.1, 12.7, 12.4, 12.0, 11.3 and 10.8 for the full
MT protein. Each line corresponds to a different metallation state: Zn0 (
), Zn1 (
), Zn2 (
), Zn3 (
), Zn4 (
), Zn5 (
), Zn6 (
) and Zn7 (
).
Reprinted with permission from Summers, K. L., Sutherland, D. E. K., and Stillman, M.
J. (2013) Single domain metallothioneins: Evidence for the onset of clustered metal
binding domains, Biochemistry 52: 2461-2471. © 2013 American Chemical Society.
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immediately indicate that the KFs for the first four Zn2+ in βα-rhMT are greater than
comparable KFs in the two domains.
The simulation of the Zn2+ distribution across the fourteen sites, when all three
recombinant proteins are mixed and Zn2+ is added stepwise, very closely models the
experimental data (Figure 3.13 B, D, F). The KF values required in the model to explain
the experimental distribution show that the first three sites in βα-rhMT bind Zn2+
preferentially because they have the highest KF values compared with those of the
isolated domains. Because all sites are in equilibrium there appears to be a distribution
between available sites, rather than a domain-specific mechanism.
The binding constants for the first three sites in βα-rhMT were not initially expected to be
greater than in the isolated domains because, at this stage in the metallation, the binding
sites are composed of terminally bound Zn2+ (ZnCys4). However, the analysis of the As3+
binding kinetics by Ngu et al. (111, 173, 174) predicted this effect. Because there are
more available sites in βα-rhMT than in the isolated domains, the KFs of the first four
sites of βα-rhMT dominate metal binding. Analysis of the Zn2+ data indicates the first
three Zn2+ bind to βα-rhMT preferentially simply because of the effect of seven sites
(compared to four in α-rhMT and three in β-rhMT). However, the relatively simple
model does not account for the greatly reduced KF for the sixth and seventh Zn2+. An
explanation of this effect is provided below.

3.3.3

Speciation during Zn2+ Metallation of the Domains

The average metallation plots for the competition experiment in which the full MT
protein and the isolated fragments compete for added Zn2+ (Figure 3.14 A, B) were
calculated from the experimental data (Figure 3.13 A, C, E). The average metallation
plots are a complicated summary that may provide insight into the buffering and Zn2+donating properties of MT (Figure 3.14). There are three main features of the data shown
in Figure 3.14 A.

First, in the presence of βα-rhMT, the β-domain binds Zn2+

preferentially over the α-domain – up to the binding of the second Zn2+. The two traces
for the isolated domains in competition with the full protein are almost identical to the
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Figure 3.14.
Experimental and
simulated metallation of apo-β-, apoα, and apo-βα-rhMT when competing
for Zn2+. (A) Average number of Zn2+
bound in the β-domain (
), the αdomain (
), and the full MT
protein (
) based on data in Figure
3.13. (B) Comparison of the average
metallated states of the sum of the two
domains (
) with the full protein (
) as a function of added Zn2+. (C)
Simulation of the distribution of Zn2+
between the three protein species using
the log10(KF) values of 12.7, 12.4 and
12.0 for the β-domain, 12.6, 12.3, 11.8
and 11.5 for the α-domain, and 13.3,
13.1, 12.7, 12.4, 12.0, 11.3 and 10.8 for
the full MT protein (from Figure 3.13).
Key features (1', 2', 3', 4', 5') in the
experimental data (in A and B) are
modelled in the simulation as well (1, 2,
3, 4, 5) (in C).
Reprinted with
permission from Summers, K. L.,
Sutherland, D. E. K., and Stillman, M.
J.
(2013)
Single
domain
metallothioneins: Evidence for the
onset of clustered metal binding
domains, Biochemistry 52: 2461-2471.
© 2013 American Chemical Society.
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traces of the two domains without competition with the full protein (Figure 3.10), which
clearly illustrates that the KF values remain constant. The simulations confirm that the KF
values are consistent with the experimental data of two separate types of competition
experiments. Second, the presence of βα-rhMT reduces the overall Zn2+ loading of the
isolated domains compared with the Zn2+ loading in the absence of βα-rhMT (Figure
3.10). This is an important effect because it means that the isolated domains are binding
proportionally less Zn2+. This buffering property results from the equilibrium between all
three species. Third, βα-rhMT dominates Zn2+ binding until the eighth Zn2+ is added to
the solution.
The average number of Zn2+ sites filled in βα-rhMT was compared with the sum of the
Zn2+ sites filled in the isolated β- and α-domains to provide a clearer indication of the
difference between two linked domains and two separate domains (Figure 3.14 B). If the
KFs were the same for each Zn2+ site (i.e., the KFs for first site in βα, β, and α were
identical), then the two lines should be coincident. Clearly, βα-rhMT binds more Zn2+
into its sites compared with the same number of sites in the domains (i.e., β- plus αrhMT), but only until the eighth Zn2+ is added.

Afterward, the isolated domains

preferentially bind more Zn2+ even though the same number of sites is available in the
full protein.
A simulation of the stepwise distribution of Zn2+ was performed based on the same KFs
as were used previously and it matches the experimental data in Figure 3.14 (A, B)
almost exactly (Figure 3.14 C). The five key features (labeled 1’-5’) on the lines in
Figure 3.14 (A, B) are reproduced exactly in the simulation (labeled 1-5; Figure 3.14 C),
confirming the reliability of the KF values used in the simulation. This provides further
support for the model, which considers diminishing KF values for all sites as well as the
advantage of the seven sites in βα-rhMT over the 4 + 3 sites in the isolated domains.

3.3.4

Cluster Formation: A Greater Reduction in KF for the
Sixth Zn2+

The isolated domains begin to bind more Zn2+ just as the sixth Zn2+ binds to βα-rhMT.
Structurally, this is where βα-rhMT must use bridging cysteinyl sulfurs to form the
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Zn6Cys20 structure from the string of five isolated, terminally coordinated ZnCys4 sites
that form the Zn5Cys20 structure. The simulation shows that the KFs for the sixth and
seventh Zn2+ sites in βα-rhMT are lower than the KFs of the fourth α-rhMT site and the
third β-rhMT site and, therefore, the isolated domains preferentially bind the incoming
Zn2+ (Figure 3.13). The first three Zn2+ binding sites in βα-rhMT exhibit higher KF
values than any sites in the isolated domains. Following the advantage of the seven
available sites in βα-rhMT compared to the three in β-rhMT and the four in α-rhMT, the
KF values of all three proteins are balanced and approximately equal once the fifth Zn2+
binds to βα-rhMT (Figures 3.13 B, D, F and Figure 3.14 C). After this point, the isolated
domains metallate at the expense of the full protein – most likely because cluster
formation in the isolated domains is not as disruptive. The drop in binding affinity for
the sixth and seventh Zn2+ sites in βα-rhMT is based on the properties of cysteine ligands.
The onset of bridging cysteinyl thiolates in βα-rhMT leads to a significant decrease in KF
after five Zn2+ have bound terminally to all twenty cysteines. The data suggest that it is
the sixth Zn2+, with a lower affinity for βα-rhMT compared to the isolated domains, that
causes bridging to occur and forces the two domain structure to form. The model
suggests massive rearrangements are necessary to change the structure from that of five
ZnCys4 units to the clustered, domain-separated Zn7Cys20 structure (Subsection 3.2.7).
The seventh Zn2+ completes the two-domain structure leading to the Zn4Cys11 α-domain
and the Zn3Cys9 β-domain.
In summary,
apo-Cys20-βα-rhMT + 5 Zn2+ → (ZnCys4)5-βα-rhMT
(ZnCys4)5-βα-rhMT + 2 Zn2+ → (Zn4Cys11 + Zn3Cys9)-βα-rhMT

3.3.5

Clues from As3+ Binding Kinetics Studies

Previous metal binding studies of rhMT 1a with As3+ demonstrated that the metal-binding
affinity of MT is directly dependent on the number of available binding sites. In fact, the
KFs essentially decreased from the first As3+ bound to the sixth bound (recall that As3+
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binds to MT using terminal cysteines only) (111, 173, 174, 200). Interestingly, a similar
trend is observed here with Zn2+ (Figure 3.13).
From the results above, it is apparent that the hypothesis by Ngu et al. (111, 173, 174,
200), in which KFs decrease from the first to the last metal bound, holds true up to the
fourth and fifth Zn2+ bound. The considerable difference between the two metal-ion
species is that Zn7-rhMT requires bridging cysteines, while bridging cannot occur in As3+
metallation, leading to As6-MT as the saturated species. Interestingly, the key species in
Zn2+ metallation is the terminally coordinated Zn5-βα-rhMT, where the KF for the
conversion of Zn5-βα-rhMT to Zn6-βα-rhMT is sufficiently low to allow near quantitative
formation of the Zn5 species.
Details from the As3+ studies, along with the new information obtained from the ESI MS
data described above, are crucial in placing Zn-MT between Zn2+ sensors that must be
present in mammalian cells (e.g., sensors similar to the bacterial ZiaR (85) and ZUR
(213)) (Subsection 1.3.3). By considering the results presented here in the context of the
cellular Zn2+ sequestration equilibrium, MT may play a key role in Zn2+ storage,
trafficking, and donation. Three main characteristics demonstrate the flexibility of MT
and may provide insight to the role of MT in Zn2+ homeostasis. First, it is evident that
the KF values are proportional to the number of available binding sites. Second, there
does not appear to be a domain preference for Zn2+ – at least until terminal thiolates
bridge to bind the sixth and seventh Zn2+. Third, bridging interactions likely lead to the
significantly decreased KF values observed. Taking these three points into consideration,
donation of the weakly bound sixth and seventh Zn2+ to apo-enzymes would not expose
any of the twenty cysteines to oxidation and would allow subsequent acquisition and
donation. However, the redox situation will be more complicated in vivo, most likely
involving the reducing effects of glutathione. In effect, the sixth and seventh Zn2+ may
act as the buffer-active Zn2+ with lower KFs than the first five structural Zn2+.

3.3.6

Clues from Previously Published Co2+ EPR Data

Cobalt, with its rich spectroscopic properties and characteristic tetrahedral coordination
with thiols, has been extensively used to mimic Zn2+ binding to MT. Cobalt EPR is
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unique because the intensity is directly related to the number of Co2+ bound to MT and
the number of non-clustered Co2+ centers. In work by Vasak and Kagi (201), metallation
of MT with Co2+ was monitored using EPR spectroscopy. Analysis of the data, when
plotted as a function of added Co2+, showed an increase in the number of free spins until
four molar equivalents had been added. After this point, antiferromagnetic coupling led
to a decrease in the signal intensity, which approached zero after the addition of seven
equivalents of Co2+. These data were interpreted as cluster formation taking place after
four metal ions had been added.
The EPR experiment was simulated using the Zn2+ data for βα-rhMT described above
(Subsection 3.2.2), which shows the distribution of metals in non-clustered sites (up to
five Zn2+ bound) and clustered sites (six and seven Zn2+ bound). A fictitious spin was
assigned to the non-bridging Zn2+ to mimic Co2+ spins and the spins were cancelled when
clustering occurred (Figure 3.15).

The following rules were used to simulate the

predicted, fictitious magnetic moment: Zn1- through Zn5-rhMT form without any
bridging interactions and, consequently, increase the EPR signal; the formation of Zn6and Zn7-rhMT require four and eight bridging interactions, respectively and,
consequently, decrease the signal due to antiferromagnetic coupling. The simulated EPR
data closely resemble the original Co2+ data with an identical maximum at four metals
added (the average number of spins are shown rather than the calculated g factor) (Figure
3.15). From the model with five terminally bound M2+, five M2+ would be predicted to
result in maximal spin intensity; however, the non-cooperative nature of metallation
requires that some M6-rhMT must also exist at this metal concentration. In the Co2+
titration, this species would greatly decrease the signal intensity. The close similarity
between the modelled data (which are based upon ESI MS speciation data) and the
original Co2+ data, provides support for the proposal that clustering does not occur until
the sixth metal ion is added and that Zn5-rhMT is a single domain species that does not
involve bridging cysteines.
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Figure 3.15. Simulated EPR data based on metallation of apo-βα-rhMT with Zn2+.
The simulated average number of spins was calculated assuming Zn2+ has the same spin
as Co2+. The exact metallation state was obtained from analysis of the data in Figure
3.12. Reprinted with permission from Summers, K. L., Sutherland, D. E. K., and
Stillman, M. J. (2013) Single domain metallothioneins: Evidence for the onset of
clustered metal binding domains, Biochemistry 52: 2461-2471. © 2013 American
Chemical Society.
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3.3.7

Molecular Modelling of a Potential Metallation Pathway

A series of molecular dynamics calculations were used to illustrate the structural changes
that occur during the progressive Zn2+ metallation of apo-βα-rhMT to the intermediate
Zn5-βα-rhMT, and finally to Zn7-βα-rhMT (Figure 3.16). The minimized apo-βα-rhMT
structure resembles that reported by Rigby et al. (126, 127, 129), showing a globular fold
with the free cysteinyl thiols aligned on the surface (Figure 3.16 A). Tetrahedral Zn2+
coordination by terminal cysteines was arranged for the first five Zn2+, forming a single
Zn5Cys20 binding domain. It is important to note that the Zn5- and Zn6-βα-rhMT species
presented are of a qualitative nature (Figure 3.16 B, C). Without definitive structural
information, alternative connectivities may be possible.

Despite the lack of cluster

formation in Zn5-βα-rhMT, the overall three-dimensional structure of the protein
resembles that of fully metallated Zn7-βα-rhMT.

Even when there are no bridging

cysteines present, the Zn5-βα-rhMT model shows two Zn2+ in the β-domain cysteines
(within residues 1 to 36) and three Zn2+ in the α-domain cysteines (within residues 37 to
74), which are spatially close to one another (Figure 3.16 B). This likely facilitates
cluster formation upon further metallation to the traditional two-domain Zn7-βα-rhMT
(Figure 3.16 D).

3.3.8 Summary
The data presented in this section are believed to show that, with the onset of cluster
formation (as defined by the use of bridging rather than terminal cysteines), there is a
significant decrease in the Zn2+ binding affinity of MT. This is highlighted in the
simulation with the decrease in KF. From the simulation of the MS data, the decreasing
KFs of a non-cooperative metallation mechanism appear to lead to formation of a stable
Zn5-βα-rhMT species, without bridging interactions. This is likely a key member of the
metallation pathway from apo-rhMT to the saturated Zn7-rhMT.
The sixth and seventh Zn2+, therefore likely act as the buffer-active Zn2+ with lower KFs
than the first five structural Zn2+, allowing MT to donate and acquire Zn2+ in vivo without
oxidizing the cysteines. In the cellular environment, this positions Zn-MT as the main
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Figure 3.16. Molecular models of possible structures formed in the metallation
pathway from apo-rhMT to Zn7-rhMT. Structural models are shown on the left and
the amino acid sequences of βα-rhMT showing the Zn2+ connectivities are shown on the
right. The backbone is depicted as a ribbon, with green spheres for Zn2+ and yellow
spheres for the sulfur atoms. The N-terminal β-domain is located on the left and the Cterminal α domain is located to the right. (A) Metal-free, apo-βα-rhMT (structure first
reported by Rigby et al. (2004) (126)). (B) Single-domain Zn5-βα-rhMT (structure
created by assigning each set of four cysteines to one Zn2+). (C) A possible structure for
Zn6-βα-rhMT using cysteines known to bridge in the saturated two-domain structure. (D)
Formation of Zn7-βα-rhMT with rearrangement of bound metals triggered by the addition
of the seventh Zn2+. Reprinted with permission from Summers, K. L., Sutherland, D. E.
K., and Stillman, M. J. (2013) Single domain metallothioneins: Evidence for the onset of
clustered metal binding domains, Biochemistry 52: 2461-2471. © 2013 American
Chemical Society.
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Zn2+ storage protein, buffering intracellular Zn2+ levels between the detection limits of
Zn2+ sensors (such as Zia (85) and ZUR (213) in microorganisms) and within the Zn2+
sequestration equilibrium.
In a recent study by Sutherland et al. (191) on the ‘supermetallation’ of MT 1a, the
addition of an eighth Cd2+ caused the two domains to coalesce into one ‘super-domain’.
When considered with the results presented here, a fundamentally altered view of the
metallation properties of MT emerges. A new structural characterization of MT where
MT exists as a flexible, single domain protein during initial metallation (< 5 equivalents)
and metallation in excess of traditional levels (> 7 equivalents) seems more plausible than
a rigid structure where the two domains are maintained regardless of metal depletion.
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4

Summary and Conclusions

New studies – particularly using ESI MS – are providing evidence for an altered binding
mechanism for metallothioneins. Before the application of ESI MS to the study of MT
metallation, many of the intermediate species were not observed, leading researchers to
believe that the protein bound metals cooperatively. Similarly, without ESI MS the
enhanced stability of the Zn5-MT species was not observed. Recently, with much wider
use of ESI MS, MT has been proposed to exhibit even more flexibility in metal binding.
In fact, MT 1a is believed to bind metals in a step-wise manner that leads to the stable
M5-MT, then saturation leads to the formation of the well-described M7-MT, and finally,
excess leads to the formation of a single-domain, ‘supermetallated’ M8-MT (where M is a
divalent metal, specifically Zn2+ or Cd2+) (191). With this new information, the in vivo
roles of MT must be reassessed; MT is now hypothesized to be a much more flexible
protein with roles in metal buffering and donation, as well as in reduction of reactive
oxygen species. MT may be able to fulfill all these roles simultaneously, with partially
metallated and partially oxidized intermediate species existing to buffer intracellular
metal concentrations and oxidative stress.

4.2 ESI MS in Metal Binding and Structural Studies
Electrospray ionization mass spectrometry has provided key information about the
mechanism of metallation of MT – specifically the metal ion speciation as a function of
metals added.

Without secondary structure, traditional spectroscopic probes do not

provide significant information about MT – especially not the apo-protein (100-102). In
addition, the essential Zn2+ stored by mammalian MT, is spectroscopically invisible
(165). Cadmium has been used as a structural probe for Zn2+ metallation in many of the
techniques used to study metalloproteins because it is isostructural to Zn2+, because
mammalian Cd-MT and Zn-MT structures are almost identical, and because it exhibits
spectral properties amenable to standard spectroscopic analyses (e.g., UV absorption, CD
and NMR spectroscopies) (116, 117, 140).
ESI MS has allowed the direct analysis of Zn-MT (168-170). ESI MS permits the
identification of the number and type of metal ions bound by analyzing any changes to
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the protein mass and charge states. Conversely, spectroscopic techniques often only
provide an average of the total metals bound. Prior to mass spectrometric analysis,
solutions of MT were thought to be homogeneous (i.e., if 1 equivalent of Cd2+ was added,
the solution would contain 100% Cd1-MT); however, it is now evident that solutions of
MT are often a distribution of metallated species (120).
Without ESI MS, the mechanism of metallation of metallothionein could not be
understood. For example, the observation of a number of intermediate species provided
evidence for a non-cooperative binding mechanism.

Because ESI MS can monitor

multiple species simultaneously (provided they have different masses), the competition
studies that ultimately resulted in stronger evidence for an important Zn5-MT species and
relative binding constants for each Zn2+ binding site in metallothionein were devised and
successfully carried out.

4.3 Non-Cooperative Zn2+ Binding to MT 1a
Many proteins do not exhibit any form of cooperativity in binding of their substrates. In
hindsight, the hypothesis that a relatively simple protein such as metallothionein would
bind metals cooperatively seems somewhat unlikely. Without any secondary structure in
the form of α-helices or β-sheets, MT is quite flexible.

MT demonstrates metal-

dependent protein folding, where metal binding dictates the tertiary structure of the
protein; therefore, upon saturation with metals, MT can be described as having a rigid
tertiary structure in the form of two distinct metal-thiolate clustered binding domains. It
is difficult to believe that binding of one metal would then increase the affinity for
additional metal ions, especially when terminally bound metals are energetically more
favourable than metal binding sites that require bridging thiolates.
The results presented in this study demonstrate that the metallation of MT with Zn2+
occurs in a non-cooperative fashion and that partially metallated species may be critical
in the intracellular balance of metal ions. Metallothionein does not simply exist as a
mixture of apo- and holo-protein as predicted by a cooperative metallation mechanism.
The intermediate species between the apo- and holo-MT proteins may be key to the metal
buffering capability of MT.
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4.4 The Role of Metallothionein in Zn2+ Homeostasis
Metallothionein is often implicated in metal-ion homeostasis and toxic metal
detoxification. MT has been shown to act as a metallochaperone, capable of transporting
essential metal ions, such as Cu+ and Zn2+, in a controlled manner. In this role, MT must
be able to deliver metal ions to apo-enzymes. To investigate this characteristic, metal
exchange experiments have been conducted in which Zn2+ from Zn7-βα-MT has been
transferred to Zn2+-dependent enzymes.

For example, m-aconitase (155), carbonic

anhydrase (156, 157) and the Gal4 transcription factor (158) can receive Zn2+ from MT.
Similarly, MT has also been shown to accept Zn2+ from the zinc finger-containing
transcription factor Sp1 (159).
Electrospray ionization mass spectral studies have previously highlighted the stability of
partially metallated MT during the transfer of Zn2+ from Zn-MT to metal ion chelators or
to an apo-enzyme (160-162).

However, the results described in this thesis provide

evidence for a significantly different way in which MT could buffer intracellular zinc
concentrations.

4.4.1

The Importance of Zn5-rhMT 1a

The structures of partially metallated MT intermediates, as well as the structure of
saturated Zn7-MT, are critical to understanding the donation of Zn2+ to apo-enzymes.
Donation of Zn2+ from the saturated protein, with collapse of the clustered binding site
structure (as proposed by a cooperative binding mechanism), would lead to subsequent
exposure of the cysteinyl thiols to the cellular environment and oxidation would rapidly
result (154, 155, 157, 158). While MT has been shown to accommodate Zn2+ into two
metal-cysteine clusters when saturated, experiments detailed herein show that Zn2+ binds
in two steps. Electrospray ionization mass spectrometric analysis of Zn2+ metallation and
simulation calculations provided the relative binding affinities, and MT was proposed to
contain five strong binding sites and two weak binding sites. The first five Zn2+ are now
believed to bind sequentially, then the clusters form with binding of the sixth and seventh
Zn2+.
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Initial metallation of MT is no longer thought to occur in a domain specific manner, but
rather the first five Zn2+ are believed to bind terminally to the twenty thiolates in a
sequential fashion. Subsequent metallation to form Zn6- and Zn7-MT requires a complete
structural rearrangement, loss of the single domain structure, and formation of the
clustered domains. Clustering takes place through bridging interactions of the thiolates,
which causes the associated reduction in KF for the last two sites. Donated Zn2+ is
thought to come from the clustered Zn7-MT and, following donation, the terminally
bound Zn2+ structure re-forms, protecting the thiols from exposure to oxidation (Figure
4.1).

This terminally coordinated Zn5-MT species can then accept Zn2+ from

metallochaperones.
On a slightly different note, the metal-binding-induced structure of MT was believed to
require translation of the entire polypeptide chain before metallation and folding could
occur, which would result in the exposure of the twenty, highly reactive thiols to the
intracellular environment (126). In light of the evidence to support a Zn5 intermediate
species, I propose an alternative hypothesis. Specifically, Zn2+ may bind to the MT
peptide as each set of four cysteines emerges during translation, resulting in the Zn5-MT
upon completion of protein translation. After this point, an additional two Zn2+ may bind
to induce formation of the well-described, two-domain Zn7-MT structure. When recent
studies on ‘supermetallated’ Cd8-MT are also considered, it would appear that the twodomain M7-MT species so often described in structural studies is a unique point in the
metallation pathway of MT. MT may exist as a single domain protein with up to five
M2+ bound and with more than seven M2+ bound.

4.5

The Role of Metallothionein in Oxidative Stress

Metallothionein is often cited as a protective agent against oxidative stress, where the
balance between apo- and holo-MT controls the redox chemistry of the cell (154, 208,
209). Considering the non-cooperative nature of the metallation of MT with zinc, the
average metal load of MT may somewhat dictate the oxidative environment of the cell.
Even though Zn5-rhMT possesses no free thiol groups, Zn5-MT should be able to take
part in cellular chemistry as a protective agent against oxidative stress.
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Figure 4.1. Schematic showing the cyclic acquisition and donation of Zn2+ by
metallothionein. Zn2+ are represented as green spheres and cysteinyl sulfurs are
represented as yellow spheres. Zn5-rhMT may buffer slight increases in intracellular
Zn2+ concentrations by accommodating an additional two Zn2+. Similarly under slightly
limiting intracellular Zn2+ concentrations, Zn7-rhMT may donate two weakly bound Zn2+
to Zn2+ dependent apo-enzymes. The ‘Zn-Chaperone’ and the ‘Zn-Enzyme’ are a ZIP
protein (PDB structure 2AJ0) and carbonic anhydrase (PDB structure 3U3A),
respectively (71, 214). Adapted with permission from Summers, K. L., Sutherland, D. E.
K., and Stillman, M. J. (2013) Single domain metallothioneins: Evidence for the onset of
clustered metal binding domains, Biochemistry 52: 2461-2471. © 2013 American
Chemical Society.
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Equilibria between apo-MT, oxidized MT and holo-MT have been suggested to affect the
stress response of organisms (208); however, metallation of MT was assumed to occur
through a cooperative mechanism. A recent report on the isolation of partially oxidized
MT from mice under oxidative stress provides further support for a role of partially
metallated MT as a protective agent against oxidative stress (206). MT is able to impact
the pathogenesis of diseases such as hyperglycemia, ischemic cardiomyopathy, type 2
diabetes, and cardiovascular complications through Zn2+ buffering and antioxidant
dysfunction, both of which rely on the metallation status of MT in vivo (215-217). The
knowledge that MT metallates non-cooperatively will aid in determining the function of
MT in these disorders. From the evidence reported here on the metallation of MT, it is
possible that MT is able to combat oxidative stress in a dynamic way, where progressive
oxidation of MT leads to the sequential release of Zn2+ ions and eventually complete
oxidation. This released Zn2+ can then bind to MTF-1 (207), Zn-MTF-1 then leads to an
upregulation of MT (and other Zn2+ binding proteins) and resistance to the oxidative
stress.

4.6 Future Directions
The novel ESI MS studies described in this thesis have opened many avenues for further
study of MT and its roles in the homeostasis of essential metals, detoxification of toxic
metals, and in protection against oxidative stress.

Future studies should attempt to

provide concrete evidence for the potential structures detailed in Figure 4.1. Crystal
structures of Zn5-MT, Zn6-MT, and Zn7-MT would greatly impact the understanding of
the structure, and therefore, function of metallothioneins in the homeostasis of zinc. In
addition, because terminal metal-thiolate bonds are thought to be shorter than bridging
bonds, a difference in M-S bond length may be observed in XAFS studies of the
terminally coordinated sites in Zn5-MT compared with the clustered binding sites in Zn7MT. With the understanding that obtaining a crystal structure is no small task, there may
be other ways to investigate the stable Zn5-MT and its potential role in buffering zinc
concentrations within a cell. For example, the available cysteines can be counted using a
covalent cysteine modifier, parabenzoquinone, which has been used previously to
investigate the structure of apo-MT and the accessibility of partially metallated MT (130,
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218). Modification of a cysteine with benzoquinone results in a mass shift of 108.09 Da
from the mass of the protein and is thus easily identified in a deconvoluted mass
spectrum. If the Zn2+ in Zn5-MT are indeed coordinated only by terminal cysteines, there
should be no sulfurs available to bind the benzoquinone. In fact, the use of benzoquinone
as a modifier of available cysteines may aid in the elucidation of the various intermediate
structures in the metallation pathway of MT.
Further investigation into the significance of the Zn5-rhMT intermediate species, through
interactions of Zn7-rhMT with Zn2+-dependent apo-enzymes, is also required.

If

formation of a Zn5-species permits donation to apo-enzymes with binding affinities on
the order of 1011 M-1, Zn7-MT should readily donate two Zn2+. In addition, a sample of
100% Zn5-MT should readily accept two Zn2+ from Zn2+ transport proteins with lower
KFs than the sixth and seventh binding sites in βα-rhMT (on the order of 1010 M-1).
Now that the metallation mechanism for Zn2+ has been well characterized, with noncooperative binding and a stable Zn5-rhMT intermediate, similar experiments are
required to decipher the binding mechanism of the other essential metal often bound by
MT in vivo, Cu+. Copper coordination is different from that of Zn2+ (digonal or trigonal
vs. tetrahedral) and therefore, the metallation pathway is not expected to be identical. It
would be of interest to investigate the existence of an intermediate Cu-MT species that
coordinates the Cu+ using only terminal cysteines. Investigation of the Cu+ metallation of
MT would be slightly more difficult than that of Zn2+ because not only will the twenty
cysteinyl sulfurs oxidize, but so will the Cu+ if exposed to oxygen.
The two-domain structure of many metallothioneins is thought to allow the protein to
function simultaneously in both Cu+ and Zn2+ homeostasis. Future metallation studies in
which metallothionein is exposed to increasing amounts of both Cu+ and Zn2+ are needed
to determine if the metallation pathway for metallothionein is different in the presence of
both metals. In particular, a competition experiment in which the domain peptides
compete for Cu+ and Zn2+ may give some indication of any domain preference for these
metals. However, such an experiment may not be easily monitored by ESI MS because
the masses of copper and zinc are quite close (63.55 and 65.38 g/mol, respectively).
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Appendix: Charge State Spectra
The following Figures, A1 and A2, are the charge state spectra that complement the
deconvoluted spectra (Figures 3.9 and 3.12, respectively). Figure A1 corresponds to the
m/z spectra recorded for the competitive titration of Zn2+ between the two isolated
domain peptides. Figure A2 corresponds to the m/z spectra recorded for the competitive
titration of Zn2+ with the two domain peptides and full MT protein.
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Figure A.1. Charge state spectra recorded during the competitive titration of β- and
α-rhMT with Zn2+. Spectral changes were recorded as aliquots of 8.3 mM ZnSO4 were
added to the solution of 29.2 µM apo-β- and apo-α-rhMT (pH 9.2) on ice. Mass spectra
were recorded at Zn2+ molar equivalents of 0.4, 2.1, 3.5, 5.4, 7.6, and 8.0. Reprinted with
permission from Summers, K. L., Sutherland, D. E. K., and Stillman, M. J. (2013) Single
domain metallothioneins: Evidence for the onset of clustered metal binding domains,
Biochemistry 52: 2461-2471. © 2013 American Chemical Society.
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Figure A.2. Charge state spectra recorded during the competitive titration of β-, α-,
and βα-rhMT with Zn2+. Mass spectra were recorded as aliquots of 7.3 mM ZnSO4
were added to a solution containing equimolar concentrations (29.9 µM) of apo-β-, apoα-, and apo-βα-rhMT (pH 7.8) at molar equivalents of 1.8, 4.6, 6.4, 9.3, 10.3 and 12.5.
Reprinted with permission from Summers, K. L., Sutherland, D. E. K., and Stillman, M.
J. (2013) Single domain metallothioneins: Evidence for the onset of clustered metal
binding domains, Biochemistry 52: 2461-2471. © 2013 American Chemical Society.
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